



CLINICAL GUIDELINES

Head Imaging Policy

Version 1.0.2019

Effective February 15, 2019



eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual's Primary Care Physician (PCP) may provide additional insight.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

HD-34: Pineal Cysts	97
HD-35: Arachnoid Cysts	98
HD-36: Nuclear Medicine	99
HD-37: Sleep-Related Requests	100

Abbreviations for Head Imaging Guidelines

ACTH	adrenocorticotrophic hormone
AD	Alzheimer's Disease
ADH	antidiuretic hormone
AION	arteritic ischemic optic neuritis
AVM	arteriovenous malformation
CBCT	Cone-beam computerized tomography
CMV	cytomegalovirus
CSF	cerebrospinal fluid
CT	computed tomography
CTA	computed tomography angiography
DNA	deoxyribonucleic acid
DWI	diffusion weighted imaging (for MRI)
EEG	electroencephalogram
ENT	Ear, Nose, Throat
ESR	erythrocyte sedimentation rate
FDG	fluorodeoxyglucose
FSH	follicle-stimulating hormone
FTD	Frontotemporal Dementia
GCA	giant cell arteritis
GCS	Glasgow Coma Scale
HIV	human immunodeficiency virus
LH	luteinizing hormone
MMSE	mini mental status examination
MRA	magnetic resonance angiography
MRI	magnetic resonance imaging
MRN	magnetic resonance neurography
MS	multiple sclerosis
MSI	magnetic source imaging
NAION	non-arteritic ischemic optic neuritis
NPH	normal pressure hydrocephalus
PET	positron emission tomography
PML	progressive multifocal leukoencephalopathy
PNET	primitive neuro ectodermal tumor
PWI	perfusion weighted imaging (for MRI)
SAH	subarachnoid hemorrhage
SIADH	Syndrome of Inappropriate Antidiuretic Hormone Secretion
SLE	systemic lupus erythematosus
TIA	transient ischemic attack
TMJ	temporomandibular joint disease
TSH	thyroid-stimulating hormone
VBI	vertebrobasilar
VP	ventriculoperitoneal
XRT	radiation therapy

HD-1: General Guidelines

HD-1: General Guidelines	6
HD-1.1: General Guidelines – Anatomic Issues	6
HD-1.2: General Guidelines – Modality	7
HD-1.3: General Guidelines – MRI Head	7
HD-1.4: General Guidelines – CT Head	7
HD-1.5: General Guidelines – CT and MR Angiography: (CTA and MRA)	8
HD-1.6: General Guidelines – PET Coding Notes	8
HD-1.7: General Guidelines – Other Imaging Situations	9

HD-1: General Guidelines

- A recent (within 60 days) face to face evaluation including a detailed history, physical examination and appropriate laboratory studies should be performed prior to considering the use of an advanced imaging (CT, MR, Nuclear Medicine) procedure. An exception can be made if the patient is undergoing a guideline-supported, scheduled follow-up imaging evaluation.
 - ◆ The clinical evaluation should include a relevant history and physical examination, including a neurological examination (unless the request is for a scheduled follow-up of known problems such as MS, tumors, or hydrocephalus, scheduled surveillance with no new symptoms, screening asymptomatic patient due to family history and otherwise meet criteria for repeat imaging), as well as appropriate laboratory studies and non-advanced imaging modalities
 - A neurological exam is required prior to advanced imaging except in the following scenarios:
 - Tinnitus, TMJ, Sinus or mastoid disease, ear pain, hearing loss and epistaxis.
 - The request is from a neurologist or neurosurgeon who has seen the patient since onset of symptoms
 - ◆ Other meaningful contact (telephone call, electronic mail or messaging) with an established patient can substitute for a face-to-face clinical evaluation

HD-1.1: General Guidelines – Anatomic Issues

- If two studies using the same modality both cover the anatomic region of clinical interest, only one is generally needed, with the exception of the following scenarios:
 - ◆ Maxillofacial CT (CPT® 70486, CPT® 70487, CPT® 70488) or orbital/temporal bone CT (CPT® 70480, CPT® 70481, CPT® 70482): both cover the structures of the orbits, sinuses, and face. Two separate imaging studies are only supported if there is suspicion of simultaneous involvement of more posterior lesions, especially of the region involving the middle or inner ear
 - ◆ Pituitary Gland: one study (either MRI Head [CPT® 70553] or MRI Orbit, Face, Neck [CPT® 70543]) is adequate to report the imaging of the pituitary. If a previous routine MRI Head was reported to show a possible pituitary tumor, a repeat MRI with dedicated pituitary protocol may be performed
 - ◆ Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT® 70540, CPT® 70542, CPT® 70543), but should not be used in conjunction with MRI Head codes (CPT® 70551, CPT® 70552, CPT® 70553) if IAC views are performed as part of the brain
 - ◆ Mandible (jaw): Maxillofacial CT (CPT® 70486, CPT® 70487, CPT® 70488) or Neck CT (CPT® 70490, CPT® 70491, CPT® 70492) can be used to report imaging of the mandible. Neck CT will also image the submandibular space
 - If MRI is indicated, MRI Orbit, Face, Neck (CPT® 70540, CPT® 70542, or CPT® 70543) can be used to report imaging of the mandible and submandibular space

- MRI of the Temporomandibular Joint(s) (TMJ) is reported as CPT® 70336. This code is inherently bilateral and should not be reported twice on the same date of service

HD-1.2: General Guidelines – Modality

- MRI is preferable to CT for most indications. For exceptions, See **HD-1.4: General Guidelines – CT Head**.
- MRI may be performed for these indications following an initial CT:
 - ◆ MRI Head without and with contrast (CPT® 70553) may be performed to follow-up abnormalities seen on CT Head without contrast (CPT® 70450) when a mass, lesion, or infection is found
 - ◆ MRI Head without contrast (CPT® 70551) or MRI Head without and with contrast (CPT® 70553) (preferred) may be performed to follow-up abnormalities seen on CT Head without contrast (CPT® 70450) when there is suspected Multiple Sclerosis or other demyelinating disease
 - ◆ MRI Head without (CPT® 70551) or MRI Head without and with contrast (CPT® 70553) may be performed to follow up on stroke or TIA when initial CT Head was done on emergent basis
 - ◆ MRI Head without and with contrast (CPT® 70553) for evaluation of new onset seizures

HD-1.3: General Guidelines – MRI Head

- MRI, with contrast, (CPT® 70552) should not be ordered except to follow-up on a very recent non-contrast study (within two weeks)

The AMA CPT manual does not describe nor assign any minimum or maximum number of sequences for any CT or MRI study. Both MRI and CT imaging protocols are often influenced by the individual clinical situation of the patient and additional sequences are not uncommon. There are numerous MRI sequences that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development. Additional sequences, however, are still performed and coded under the routine MRI Brain CPT® 70551, CPT® 70552, or CPT® 70553.

HD-1.4: General Guidelines – CT Head

- Scenarios in which MRI is contraindicated (i.e. pacemakers, ICDs, cochlear implants, aneurysm clips, orbital metallic fragments, etc.)
- Head CT without contrast (CPT® 70450) in nearly all cases, to show:
 - ◆ Mass effect
 - ◆ Blood/blood products
 - ◆ Urgent/emergent settings due to availability and speed of CT
 - ◆ Trauma
 - ◆ Recent hemorrhage, whether traumatic or spontaneous
 - ◆ Bony structures of the head evaluations

- ◆ Hydrocephalus evaluation and follow-up (some centers use limited non-contrast “fast or rapid MRI” (CPT® 70551) to minimize radiation exposure in children - these requests may be approved).
- ◆ Prior to lumbar puncture in patients with cranial complaints (without contrast) (CPT® 70450)

HD-1.5: General Guidelines – CT and MR Angiography: (CTA and MRA)

- Head MRA (CPT® 70544) is generally done without contrast
- MRA Neck may be done either without contrast, with contrast, or without and with contrast, depending on facility preference and protocols and type of scanner
- Head MRA or CTA may be considered with suspected intracranial vascular disease, for example:
 - ◆ Pulsatile tinnitus
 - ◆ Hemifacial spasm if consideration for surgical decompression
 - ◆ Evaluation of stroke or TIA (See **HD-21: Stroke/TIA**)
 - ◆ Trigeminal neuralgia failed medical therapy
 - ◆ Cerebral sinus thrombosis suspected with increased intracranial pressure (refractory headaches, papilledema, diagnosis of pseudotumor cerebri)
 - ◆ Aneurysm suspected with acute “thunderclap” headache syndrome and appropriate screening or evaluation of known subarachnoid hemorrhage
 - ◆ Intra-cranial pre-operative planning if there is concern of possible vascular involvement or risk for vascular complication from procedure
 - ◆ Suspicion of vasculitis based on supporting clinical evidence
 - ◆ NOTE: Evaluation of posterior circulation disease requires both neck and head MRA/CTA to visualize the entire vertebral-basilar system.
 - ◆ CTA or MRA Head without or with or without and with contrast for follow up of aneurysm clipping or coiling procedures (See **HD-12.1: Intracranial Aneurysms**)
- CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart:
 - ◆ If arterial and venous CT or MR studies are both performed in the same session, only **one** CPT® code should be used to report both procedures
 - ◆ MRA without and with contrast with venous sinus thrombosis to differentiate total from subtotal occlusion

HD-1.6: General Guidelines – PET Coding Notes

- Metabolic Brain PET should be reported as Metabolic Brain PET (CPT® 78608)
- Amyloid Brain PET should be reported as limited PET (CPT® 78811) or limited PET/CT (CPT® 78814)

HD-1.7: General Guidelines – Other Imaging Situations

- Nausea and vomiting, persistent, unexplained and a negative GI evaluation: can undergo MRI Head without contrast (CPT® 70551)
- See **AB-1.10: Special Considerations** in the Abdomen Imaging Guidelines
- ECT treatment to screen for intracranial disease: can undergo either MRI Head without contrast (CPT® 70551) or Head CT without contrast (CPT® 70450)
- Screening for metallic fragments before MRI should be done initially with plain x-ray.
 - ◆ The use of Orbital CT to rule out orbital metallic fragments prior to MRI is rarely necessary
 - ◆ Plain x-rays are generally sufficient; x-ray detects fragments of 0.12 mm or more, and CT detects those of 0.07 mm or more
- Plain x-ray is generally sufficient to screen for aneurysm clips
- CPT® 76377 (3D rendering requiring image post-processing on an independent workstation) can be considered when performed in conjunction with conventional angiography (i.e.: conventional 4 vessel cerebral angiography).

References

1. Grossman RI, Yousem DM. *Neuroradiology*. Philadelphia, PA: Mosby Elsevier; 2010.
2. Latchaw RE, Kucharczyk J, Moseley ME. *Imaging of the nervous system: diagnostic and therapeutic applications*. Philadelphia: Elsevier Mosby; 2005.
3. Rowland LP, Pedley TA, Merritt HH. *Merritt's neurology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
4. Menkes JH, Sarnat HB, Maria BL. *Child neurology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.

HD-2: Taste and Smell Disorders

HD-2.1: Taste and Smell Disorders

11

HD-2.1: Taste and Smell Disorders

- MRI Head without and with contrast (CPT® 70553) or without contrast (CPT® 70551) is considered with unexplained unilateral or bilateral anosmia (inability to perceive odor) or dysgeusia (loss of taste)^{1,2}
- If sinus or facial bone disorders is suspected, then consider initially Maxillofacial CT without contrast (CPT® 70486)²

References

1. Policeni B, Corey AS, Burns J, et al. *ACR Appropriateness Criteria®* Cranial neuropathy. Revised 2017. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69509/Narrative/>
2. DeVere R. Disorders of taste and smell. *Continuum*. 2017 Apr;23(2):421-446. Accessed October 11, 2017. <https://insights.ovid.com/crossref?an=00132979-201704000-00009>.

HD-3: Ataxia

HD-3.1: Ataxia

13

HD-3.1: Ataxia

- MRI Head without and with contrast (CPT® 70553) or MRI Head without contrast (CPT® 70551) is considered in all patients with ataxia:¹
 - ◆ If spinal disease is suspected **add** MRI Cervical, Thoracic and/or Lumbar spine without contrast (CPT® 72141, CPT® 72146, CPT® 72148)¹
 - ◆ If these symptoms are acute and stroke is suspected See **HD-21: Stroke/TIA**
 - ◆ If MS is suspected, See **HD-16: Multiple Sclerosis (MS) and Related Conditions**
 - ◆ If these symptoms are acute following head trauma, CT Head without contrast (CPT® 70450) and/or CT Temporal Bone without contrast (CPT® 70480) can be added¹

Reference

1. Broderick DF, Wippold II FJ, Cornelius RS, et al. *ACR Appropriateness Criteria®* Ataxia. Date of origin: 1999. Last review date: 2012. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69477/Narrative/>

HD-4: Behavioral Disorders

HD-4: Behavioral Disorders – General Information	15
HD-4.1: Behavioral Disorders	15

HD-4: Behavioral Disorders – General Information

Autism: See **PEDHD-17: Autism Spectrum Disorders**

HD-4.1: Behavioral Disorders

Neuroses and psychoses do not routinely need advanced imaging:

- Bipolar disorder, schizophrenia, and related disorders may require advanced imaging in the following clinical circumstances:
 - ◆ Atypical clinical presentation
 - Acute onset
 - Late onset over age 40
 - Presents in setting of general medical illness or intensive care setting
 - Non-auditory hallucinations (e.g., visual, tactile, olfactory)
 - Patients who fail to respond to treatment in the expected manner and who manifest features suggestive of an organic brain disorder (for example, focal deficits, severe headache, or seizures) may undergo
- MRI Head without contrast (CPT® 70551) or MRI Head without and with contrast (CPT® 70553), or CT Head without contrast (CPT® 70450)

References

1. Ropper AH and Brown RH. *Adams and Victor's principles of neurology*. 8th Ed. New York: McGraw-Hill Companies, Inc. 2005.1285-1332.
2. Rowland LP, Pedley TA, Merritt HH. *Merritt's neurology*. 12th Ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2010; 1053-1075.
3. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd Ed. American Psychiatric Association. Feb. 2004.

HD-5: Chiari and Skull-Base Malformation

See Pediatric Head Guidelines, [PEDHD-9: Chiari and Skull Base Malformations](#)

HD-6: Facial Palsy (Bell's Palsy)

HD-6.1: Facial Palsy	18
HD-6.2: Hemifacial Spasm	18

HD-6.1: Facial Palsy

Typical features of Bell's palsy include spontaneous onset over 72 hours, otherwise normal neurological and systemic examination, variable initial ipsilateral temporal and auricular pain, and slow improvement over several months. Unless "red flags" are present, imaging is not necessary.

- MRI Brain without and with contrast (CPT® 70553) or MRI Head without contrast (CPT® 70551) (with attention to posterior fossa and IACs) is considered with the following "red flags" of unexplained facial paresis/paralysis in clinical scenarios with:^{1,2}
 - ◆ Trauma to the temporal bone²
 - ◆ History of tumor² systemic cancer, HIV or Lyme disease
 - ◆ No improvement in 8 weeks¹
 - ◆ No full recovery in 3 months²
 - ◆ Gradual onset over weeks to months
 - ◆ Vertigo or hearing loss
 - ◆ Bilateral involvement
 - ◆ Other atypical or Inconsistent features² including:
 - Second episode of paralysis on the same side²
 - Paralysis of isolated branches of the facial nerve²
 - Paralysis associated with other cranial nerves²
- MRI Head without and with contrast (CPT® 70553) may be considered for known sarcoidosis with suspected neurosarcoid or CNS involvement

HD-6.2: Hemifacial Spasm

- MRI Brain without and with contrast (CPT® 70553)
- May add CTA Head (CPT® 70496) or MRA Head (CPT® 70544) prior to a vascular decompression surgical procedure to clarify the vascular anatomy in patients who have failed conservative medical management

References

1. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline. Bell's Palsy Executive Summary. *Otolaryngol. Head Neck Surg.* 2013 Nov 4;149(5):656-663. Accessed October 11, 2017. <http://journals.sagepub.com/doi/10.1177/0194599813506835>
2. Policeni B, Corey AS, Burns J, et al. ACR Appropriateness Criteria® Cranial neuropathy. *American College of Radiology (ACR)*. Revised 2017. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69509/Narrative/>.
3. Iannuzzi MC, Rybicki BA, and Teirstein AS. Sarcoidosis. *N Engl J Med.* 2007 Nov 22;357(21):2153-2165. Accessed October 11, 2017. <http://www.nejm.org/doi/full/10.1056/NEJMra071714#t=article>
4. Joseph FG and Scolding NJ. Sarcoidosis of the nervous system. *Pract Neurol.* 2007 Aug; 7(4):234-244. Accessed October 11, 2017. <http://pn.bmj.com/content/7/4/234>
5. Ullapalli D and Phillips II LH. Neurosarcoidosis. *Curr Neurol Neurosci Rep.* 2004 Nov;4(6):441-447. Accessed October 11, 2017. <https://link.springer.com/article/10.1007/s11910-004-0066-9>
6. Yaltho TC and Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. *Mov Disord.* 2011 Aug 1; 26(9):1582-1592. Accessed October 11, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/mds.23692/abstract>
7. Reich, Stephen. Bell's Palsy. *Continuum.* 2017 Apr;23(2):447-466. Accessed October 11, 2017. <https://insights.ovid.com/crossref?an=00132979-201704000-00010>.

HD-7: Recurrent Laryngeal Palsy

HD-7.1: Recurrent Laryngeal Palsy

20

HD-7.1: Recurrent Laryngeal Palsy

The following can be considered with unilateral vocal cord/fold palsy identified by laryngoscopy¹

- MRI Head without and with contrast (CPT® 70553) or MRI Head without contrast (CPT® 70551)
- CT Neck with contrast (CPT® 70491) or MRI Neck without and with contrast (CPT® 70543)
- CT Chest with contrast (CPT® 71260) may be added with left vocal cord palsy¹

Reference

1. Policeni B, Corey AS, Burns J, et al. ACR Appropriateness Criteria® Cranial neuropathy. *American College of Radiology (ACR)*. Revised 2017. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69509/Narrative/>.

HD-8: Dementia

HD-8.1: Dementia	22
HD-8.2: Dementia – PET	22

HD-8.1: Dementia

MRI Head without contrast (CPT® 70551) or MRI Head without and with contrast (CPT® 70553) or CT Head without contrast (CPT® 70450) is considered after an initial clinical diagnosis of dementia^{3,4} has been established based on a detailed history of memory loss with impairment of day-to-day activities confirmed by family members or others with knowledge of the patient's status and/or abnormal bedside mental status testing such as Mini-Mental Status Exam (MMSE) with score <26, Montreal Cognitive Assessment Survey (MoCA) with score <26, Memory Impairment Screen (MIS) with score <5, and the St. Louis University Mental Status (SLUMS) with score <21. Neuropsychological testing can be performed when history and bedside mental status examination cannot provide a confident diagnosis^{1,2}.

Practice Notes

3D analysis of the temporal lobes and hippocampus (also known as volumetric analysis or Neuro Quant) lacks sufficient specificity and sensitivity to be clinically useful in the evaluation or follow up of patient with dementia, and its use is limited to research studies.

HD-8.2: Dementia - PET

Send these requests for Medical Director review. Amyloid Brain PET (CPT® 78811 or CPT® 78814) imaging is considered experimental and investigational in the diagnosis of Alzheimer's disease and in differentiating between Alzheimer's disease and other neurodegenerative/neurologic disorders.^{3,4,5} Amyloid PET studies may be approved one time for Medicare patients enrolled in approved clinical trials under Coverage with Evidence Development (CED) program. For CMS, approval with CED is available for patients enrolled in studies approved by CMS. See the link below for a list of the CMS approved clinical trials: <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Amyloid-PET.html>

- FDG Brain PET (CPT® 78608) is considered experimental and investigational in the diagnosis of Alzheimer's disease and in differentiating between Alzheimer's disease and other neurodegenerative/neurologic disorders
 - ◆ CPT® 78608 is used to report FDG PET metabolic brain studies for dementia, seizure disorders, and dedicated PET tumor imaging studies of the brain
 - ◆ CPT® 78609 is used to report PET Brain perfusion studies that are not performed with FDG. These scans are nationally noncovered by Medicare
 - ◆ Amyloid-beta (Aβ) Brain Studies:
 - Medicare will reimburse for Brain PET only through CED
 - Only one study will be paid per beneficiary and the radiopharmaceutical must be FDA-approved. As of September 2, 2016, examples of radiopharmaceuticals which met this qualification include Amyvid™ (florbetapir F18), Neuraceq™ (florbetaben F18) and Vizamyl™ (flutemetamol F18)

- ◆ FDG PET for Dementia and Neurodegenerative Diseases
 - Medicare covers FDG PET for individuals with a recent diagnosis of dementia and documented cognitive decline of at least six months who meet diagnostic criteria for both Alzheimer's disease (AD) and Frontotemporal Dementia (FTD).
 - The individual must have been evaluated for specific alternate neurodegenerative diseases or other causative factors, but the etiology of the symptoms remains unclear
 - Other conditions must also be met. For the complete coverage policy, see the Medicare National Coverage Determinations (NCD) Manual, Section 220.6.13
 - Medicare also covers FDG PET for individuals with mild cognitive impairment or early dementia when the study is performed in the context of a CMS-approved clinical trial. Requirements are detailed in Section 220.6.13 of the NCD Manual
 - All other uses of FDG PET for patients with a presumptive diagnosis of dementia-causing neurodegenerative disease for which CMS has not specifically indicated coverage continue to be noncovered. Examples of noncovered indications described in the NCD include: possible or probable Alzheimer's disease (AD), clinically typical fronto-temporal dementia (FTD), dementia of Lewy bodies, and Creutzfeldt-Jacob disease

http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/ncd103c1_Part4.pdf

<https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Amyloid-PET.html>

Practice Notes

The frontotemporal dementias (FTDs) are a group of neurodegenerative disorders that differ from Alzheimer's disease. The basic pathology involves accumulation of tau proteins in the brain rather than amyloid. Onset tends to be younger (less than 65) and progression usually more rapid than in senile dementia-Alzheimer type (SDAT). There is no treatment, and the medications used to help memory in Alzheimer's disease are not effective.

There are several subtypes of FTD; most common are the behavioral variant with early loss of executive functions, impaired judgment disinhibition and impulsivity, and the semantic variant with primary and progressive loss of language ability. Other less common subtypes include progressive supranuclear palsy, corticobasal syndrome, and FTD associated with motor neuron disease.

Diagnosis is based on clinical features, neuropsychological testing, and brain imaging (preferably MRI) to rule out other structural disease. Metabolic (FDG) PET Brain may also be helpful by demonstrating patterns of abnormality more consistent with FTD than Alzheimer's disease.

For additional information: <http://www.alz.org/dementia/fronto-temporal-dementia-fts-symptoms.asp>.

References

1. McKhann GM, Knopman DS, Chertkow, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011 May;7(3):263-269. Accessed October 11, 2017. [http://www.alzheimersanddementia.com/article/S1552-5260\(11\)00101-4/fulltext](http://www.alzheimersanddementia.com/article/S1552-5260(11)00101-4/fulltext)
2. APPENDIX: AAN guideline for clinicians: detection, diagnosis, and management of dementia. *CONTINUUM: Lifelong Learning in Neurology*. 2008 Apr;14(2), Neurogenetics:149-152. Accessed October 11, 2017. http://journals.lww.com/continuum/Citation/2008/04000/APPENDIX_AAN_Guideline_for_Clinicians_Detection,.11.aspx
3. Decision Memo for Positron Emission Tomography (FDG) for Alzheimer's Disease/Dementia (CAG-00088N). *CMS.gov*. Centers for Medicare & Medicaid Services. Accessed October 11, 2017. <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=64&fromdb=true>.
4. Wippold II FJ, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria® Dementia and movement disorders. *American College of Radiology (ACR)*. Last review date: 2015. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69360/Narrative/>
5. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. *Neurology*. 2001 May 8;56(9):1143-1153. (May 2001; reaffirmed February 2004.) Accessed October 11, 2017. <http://www.neurology.org/content/56/9/1143.full>
6. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. *Alzheimers Dement*. 2013 Jan;9(1):e1-16. Accessed October 11, 2017. [http://www.alzheimersanddementia.com/article/S1552-5260\(13\)00034-4/fulltext](http://www.alzheimersanddementia.com/article/S1552-5260(13)00034-4/fulltext)
7. Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG-00088R). *CMS.gov*. Centers for Medicare & Medicaid Services. Accessed October 11, 2017. [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+\(FDG\)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+\(1st+Recon\)&bc=AiAAAAAAEAAA&](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+(FDG)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+(1st+Recon)&bc=AiAAAAAAEAAA&)
8. NCD for FDG PET for Dementia and Neurodegenerative Diseases (220.6.13), Effective date 4/3/2009, Implementation date 10/30/2009. Accessed October 11, 2017. <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=288&ncdver=3&bc=BAABAAAAAAA&>.
9. Albert M, DeCarli D, DeKosky S, et al. The use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment: a consensus report. 2004. Accessed October 11, 2017. https://www.alz.org/national/documents/imaging_consensus_report.pdf.

HD-9: Epilepsy/Seizures

HD-9.1: Epilepsy/Seizure

26

HD-9.1: Epilepsy/Seizures

- MRI Head without and with contrast (CPT® 70553) or MRI Head without contrast (CPT® 70551) may be considered
 - ◆ For refractory or drug resistant seizures
 - ◆ For preoperative planning
 - PET (CPT® 78608) can be considered for planning in patients with seizures who are candidates for surgical treatment¹
- MRI Head without and with contrast (preferred study) (CPT® 70553) or MRI Head without contrast (CPT® 70551) may be considered
 - ◆ For new onset seizures
 - ◆ If CT Head was performed for an initial evaluation, MRI (as described above) may be approved for additional evaluation
 - ◆ Follow-up studies after a previous routine normal study may be considered if performed with special “Epilepsy Protocol” (typically 3T magnet, thin sections with angled slices through hippocampus and temporal lobes)
- FDG PET for Refractory Seizures
 - ◆ Medicare covers FDG PET for pre-surgical evaluation for the purpose of localization of a focus of refractory seizure activity.
 - ◆ The complete coverage policy is found in the Medicare National Coverage Determinations (NCD) Manual, Section 220.6.9: http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/ncd103c1_Part4.pdf

References

1. Luttrull MD, Cornelius RS, Angtuaco EJ, et al. ACR Appropriateness Criteria® Seizures and epilepsy. *American College of Radiology (ACR)*. Last review date: 2014. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69479/Narrative/>
2. Krumholz A, Wiebe S, Gronseth G, et al. Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2007 Nov 20; 69(21):1996-2007. Accessed October 11, 2017. <http://www.neurology.org/content/69/21/1996.full>
3. Harden CL, Huff JS, Schwartz TH, et al. Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2007 Oct 30;69(18):1772-1780. Accessed October 11, 2017. <http://www.neurology.org/content/69/18/1772.full>
4. Hirtz D, Ashwal S, Berg A, et al. Practice parameter: evaluating a first nonfebrile seizure in children, report of the Quality Standards Subcommittee of the American Academy of Neurology, the Child Neurology Society, and the American Epilepsy Society. *Neurology*. 2000 Sep 12;55(5):616-623. Accessed October 11, 2017. <http://www.neurology.org/content/55/5/616.full>
5. St. Louis EK and Cascino GD. Diagnosis of epilepsy and related episodic disorders. *Continuum*. 2016; 22(1 Epilepsy):15-37. Accessed October 11, 2017. http://journals.lww.com/continuum/Abstract/2016/02000/Diagnosis_of_Epilepsy_and_Related_Episodic.6.aspx

HD-10: Facial Pain/Trigeminal Neuralgia

HD-10.1: Facial Pain/Trigeminal Neuralgia

28

HD-10.1: Facial Pain/Trigeminal Neuralgia

- MRI head without and with contrast (CPT® 70553) (with special attention to the skull base), and/or facial imaging orbital MRI without and with contrast (CPT® 70543) may be of value in a given case, including:
 - ◆ Suspected tic douloureux or one of its cranial nerve variants such as glossopharyngeal neuralgia (CN IX)
 - ◆ Concern about an underlying diagnosis of multiple sclerosis.
 - ◆ Trigeminal neuralgia which involves the ophthalmic nerve, (periorbital or forehead pain), once post-herpetic neuralgia (a complication of shingles) has been excluded by history
 - ◆ See **HD-1.5: General Guidelines - CT and MR Angiography: (CTA and MRA)**
 - ◆ See **HD-6.2: Hemifacial Spasm**

Practice Notes

The differential diagnosis of facial pain is extensive, complex, and difficult, and there is considerable case-to-case variation in optimal imaging pathway.

References

1. Goh BT, Poon CY, and Peck RH. The importance of routine magnetic resonance imaging in trigeminal neuralgia diagnosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2001 Oct; 92(4):424-429. Accessed October 11, 2017. [http://www.oooojournal.net/article/S1079-2104\(01\)56163-6/fulltext](http://www.oooojournal.net/article/S1079-2104(01)56163-6/fulltext)
2. Yaltho TC and Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. *Mov Disord.* 2011 Aug 1;26(9):1582-1592. Accessed October 11, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/mds.23692/abstract>
3. Cruccu G. Trigeminal Neuralgia. *Continuum.* 2017 Apr;23(2):396-420. Accessed October 10, 2017. http://journals.lww.com/continuum/Abstract/2017/04000/Trigeminal_Neuralgia.8.aspx.

HD-11: Headache

HD-11.1: Headache Non-Indications	30
HD-11.2: Abnormal Findings on Examination	30
HD-11.3: Sudden Onset of Headache	31
HD-11.4: Trigeminal Autonomic Cephalgias	31
HD-11.5: Skull Base, Orbit, Periorbital or Oromaxillary	31
HD-11.6: Suspected Intracranial Extension of Sinusitis or Mastoiditis	32
HD-11.7: New Headache Onset Older than Age 50	32
HD-11.8: Cancer or Immunosuppression	32
HD-11.9: Prothrombotic States	32
HD-11.10: Pregnancy	32
HD-11.11: Physical Exertion	33
HD-11.12: Post-Trauma	33
HD-11.13: Acute Systemic Infections	33
HD-11.14: Hydrocephalus Shunts	33
HD-11.15: Low Pressure Headache and CSF Leak	33

HD-11.1: Headache Non-Indications

Neuroimaging is not usually warranted in patients with migraine and a normal neurologic examination.⁴

- Advanced imaging of the head is NOT indicated for any of the following:
 - ◆ Primary headache disorder in the absence of focal neurological deficits or “red flags” (headaches that meet criteria for migraine or tension variety) (See **HD-11.2: Headaches with Red Flags**)
 - ◆ Chronic headaches or intermittent recurring headaches with a normal exam, no significant recent changes in pattern or character of headache
 - ◆ A new, recent onset headache without “red flags” or findings such as focal deficits, papilledema, age over 50, headache that awakens patient from sleep, or “thunderclap” headache

Practice Notes

Cervicogenic Headache - Defined as headaches caused by a disorder of the cervical spine, usually accompanied by neck pain or other signs and symptoms of cervical disease. Typical findings include reduced cervical range of motion, side-locked pain, and symptoms exacerbated by provocative maneuvers such as head movement or digital pressure. If suspected clinically, MRI Cervical Spine without contrast (CPT® 72141) or MRI Cervical Spine without and with contrast (CPT® 72156) if suspicion of infection, neoplasm or recent surgery. See **SP-3: Neck (Cervical Spine) Pain Without/With Neurological Features and Trauma**

HD-11.2: Headaches with Red Flags

- Red Flags:
 - ◆ Unusual symptoms or history (fever, cancer history, immunosuppression, sudden onset, new onset age > 50, history of head trauma, headache awakens patient from sleep, headache precipitated by cough or valsalva); OR
 - ◆ Abnormal examination findings (altered mental status, papilledema, focal signs or symptoms, headache accompanied by seizures, meningismus)
- Chronic headache with significant change in character, severity or frequency of headache or transformation to chronic daily headache, or development of any “red flag” findings noted above
- If any of the above abnormal findings are present, the following advanced imaging studies may be considered:
 - ◆ MRI head without and with contrast (preferred study) (CPT® 70553); or
 - ◆ MRI head without contrast (CPT® 70551); or
 - ◆ CT head without contrast (CPT® 70450)
 - ◆ MRA/MRV (CPT® 70544) or CTA/CTV (CPT® 70496) can be added to evaluate the recent onset of a progressive, severe, daily headache, with or without papilledema.

See **HD-17: Papilledema/Pseudotumor Cerebri**

HD-11.3: Sudden Onset of Headache

- For sudden onset of headache including:
 - ◆ Worst, most severe headache ever experienced or thunderclap-type^{1,2,6} (example: awakening from sleep)^{2,4}
 - ◆ Sudden onset unilateral headache, suspected carotid or vertebral dissection or ipsilateral Horner syndrome¹
- If any of these onset of headache features are present, the following advanced imaging studies may be considered:
 - ◆ CT Head without contrast (preferred study) (CPT[®] 70450); **or**
 - ◆ MRI Head without contrast (CPT[®] 70551) **or** MRI without and with contrast (CPT[®] 70553) **and**
 - ◆ CTA Head with contrast (CPT[®] 70496); **or**
 - ◆ MRA Head without and with contrast (CPT[®] 70546); **or**
 - ◆ MRA Head without contrast (CPT[®] 70544); **or**
 - ◆ If arterial dissection is suspected an MRA Neck or CTA Neck may also be performed

See **HD-12.1: Intracranial Aneurysms** and **HD-21.1: Stroke/TIA**

HD-11.4: Trigeminal Autonomic Cephalgias

- Trigeminal autonomic cephalgias includes cluster headache short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndromes; hemicrania continua.
 - ◆ May also include one-time pituitary screening^{1,12}
- Cluster Headache (may also include pituitary)
- The following advanced imaging studies may be considered for trigeminal autonomic cephalgias and cluster headache:
 - ◆ MRI Head without and with contrast (preferred study) (CPT[®] 70553); **or**
 - ◆ MRI Head without contrast (CPT[®] 70551)

See **HD-10: Facial Pain/Trigeminal Neuralgia**

HD-11.5: Skull Base, Orbit, Periorbital or Oromaxillary

- Skull base, orbital, periorbital or oromaxillary¹ imaging is appropriate for concern of skull base tumors in patients with head and neck cancers, other skull base abnormalities seen on previous imaging, any invasive sinus infections as well as sinus tumors or orbital tumors with intracranial extension. In these clinical scenarios, any one of the following procedures may be considered:
 - ◆ MRI Head and Orbits without and with contrast (preferred study) (CPT[®] 70553 and CPT[®] 70543); **or**
 - ◆ MRI Head and Orbits without contrast (CPT[®] 70551 and CPT[®] 70540); **or**
 - ◆ CT Head and Orbits without and with contrast (CPT[®] 70470 and CPT[®] 70482); **or**
 - ◆ CT Head and Orbits with contrast (CPT[®] 70460 and CPT[®] 70481)

HD-11.6: Suspected Intracranial Extension of Sinusitis or Mastoiditis

- For suspected intracranial extension of sinusitis or mastoiditis¹, **not** cervicogenic
 - ◆ MRI Head without and with contrast (CPT[®] 70553) may be considered (See **HD-29: Sinusitis**)

HD-11.7: New Headache Onset Older than Age 50

- For new onset headache in patients older than 50 years of age^{2,6} the following may be considered:
 - ◆ MRI Head without and with contrast (preferred study) (CPT[®] 70553); **or**
 - ◆ MRI Head without contrast (CPT[®] 70551);
 - ◆ If Giant Cell Arteritis is suspected, MRA Head without and with contrast (CPT[®] 70546) may be added.

HD-11.8: Cancer or Immunosuppression

- For new headache in patients with cancer or who are immunocompromised, the following may be considered:
 - ◆ MRI Head without and with contrast (preferred study) (CPT[®] 70553); **or**
 - ◆ MRI Head without contrast (CPT[®] 70551)

HD-11.9: Prothrombotic States

- For Prothrombotic states¹ including anticoagulation, the following may be considered:
 - ◆ MRI Head without and with contrast (CPT[®] 70553); **or**
 - ◆ CT Head without contrast (CPT[®] 70450)
 - ◆ If there is concern for venous sinus thrombosis in those with hypercoagulable states, MRA/MRV (CPT[®] 70544) or CTA/CTV (CPT[®] 70496) may be added
- Taking one or more anticoagulants is a red flag for headaches or head trauma and imaging is indicated. Anticoagulants include warfarin, Arixtra, Xarelto, Eliquis, Savaysa, Heparin, Fragmin, Innohep, Lovenox, Orgaran, Angiomax, Pradaxa, Acova, Iprivask and Refludan.
- Taking two or more antiaggregants is a red flag for headaches or head trauma and imaging is indicated. Antiaggregants include aspirin, Plavix, Aggrenox, Brilinta, Pravigard, Pletal, Effient, Kengreal, Persantine, and Ticlid.

HD-11.10: Pregnancy

- For new onset headache in pregnancy,¹ the following may be considered:
 - ◆ MRI Head without contrast (Gadolinium relatively contraindicated in pregnancy) (CPT[®] 70551)
 - ◆ MRA/MRV (CPT[®] 70544) or CTA/CTV (CPT[®] 70496) may be added if there is concern for venous sinus thrombosis.

HD-11.11: Physical Exertion

- For onset of headache with Valsalva maneuver,^{2,6} cough, physical exertion **or** sexual (post-coital) activity,^{1,6} but not merely a worsening of a pre-existing headache with these activities, the following procedures may be considered:
 - ◆ MRI Head without and with contrast (preferred study) (CPT® 70553); **or**
 - ◆ MRI Head without contrast (CPT® 70551); **or**
 - ◆ CT Head without contrast (CPT® 70450); **and**
 - ◆ MRA Head without contrast (CPT® 70544) **or**
 - ◆ CTA Head without and with contrast (CPT® 70496)

HD-11.12: Post-Trauma

- For post-traumatic headaches within 2 weeks of the injury See **HD-13: Head Trauma**
- For post-traumatic headaches persisting for longer than 2 weeks following the injury, but within one year of the injury, the following may be considered:
 - ◆ CT Head without contrast (CPT® 70450); **or**
 - ◆ MRI Head without contrast (CPT® 70551); **or**
 - ◆ MRI Head without and with contrast (CPT® 70553)

HD-11.13: Acute Systemic Infections

- For acute systemic infections with meningeal neck stiffness^{1,6} the following may be considered:
 - ◆ MRI Head without and with contrast (preferred study) (CPT® 70553); **or**
 - ◆ MRI Head without contrast (CPT® 70551)

HD-11.14: Hydrocephalus Shunts

- For new onset of headache or neurologic deficits in adults with known hydrocephalus and shunts, the following may be considered:
 - ◆ MRI Head without and with contrast (CPT® 70553); **or**
 - ◆ CT Head without contrast (CPT® 70450); **or**
 - ◆ MRI Head without contrast (CPT® 70551)

HD-11.15: Low Pressure Headache and CSF Leak

Evaluation of suspected low pressure headache and CSF leak may include MRI Head without and with contrast (CPT® 70553) and MRI Cervical, Thoracic and Lumbar spine, which according to facility protocols may be completed without contrast (CPT® 72141, CPT® 72146, and CPT® 72148), with and without contrast (CPT® 72156, CPT® 72157, and CPT® 72158) or with contrast only (CPT® 72142, CPT® 72147, and CPT® 72149) or CT myelography (CT Cervical, Thoracic, and Lumbar spine with contrast [CPT® 72126, CPT® 72159, CPT® 72132])

References

1. Hainer BL and Matheson EM. Approach to acute headache in adults. *Am Fam Physician*. 2013 May;87(10):682-687. Accessed October 11, 2017. <http://www.aafp.org/afp/2013/0515/p682.html>
2. Douglas AC, Wippold FJ, Broderick DF, et al. ACR Appropriateness Criteria® Headache. *American College of Radiology (ACR)*. Last review: 2013. Accessed October 11, 2017. <https://acsearch.acr.org/docs/69482/Narrative/>
3. Neff MJ. Evidence-based guidelines for neuroimaging in patients with nonacute headaches. *Am Fam Physician*. 2005 Mar 15; 71(6):1219-1222. Accessed October 11, 2017. <http://www.aafp.org/afp/2005/0315/p1219.html>
4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000 Sep 26;55(6):754–763. Accessed October 11, 2017. <http://www.neurology.org/content/55/6/754.full> Correction: *Neurology*. 2001;56(1):142-142. doi:10.1212/wnl.56.1.142-a. <http://www.neurology.org/content/56/1/142.2.full>
5. Beithon J, Gallenberg M, Johnson K, et al. Diagnosis and treatment of headache. *Institute for Clinical Systems Improvement*. Eleventh Edition. January 2013. Accessed October 11, 2017. <http://staywell.com/wp-content/uploads/2013/12/Headache0113.pdf>
6. Callaghan BC, Kerber KA, Pace RJ, et al. Headaches and Neuroimaging. *JAMA Intern Med*. 2014 May; 174(5):819-821. Accessed October 11, 2017. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1835347>
7. Newman LC. Trigeminal autonomic cephalgias. *Continuum*. 2015 Aug;21(4):1041-1057. Accessed October 11, 2017. http://journals.lww.com/continuum/Abstract/2015/08000/Trigeminal_Autonomic_Cephalalgias.12.aspx
8. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211. http://www.ihs-headache.org/binary_data/3245_ichd-3-cephalgia-2018-issue-1.pdf
9. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. *The Lancet Neurology*. 2009;8(10):959.

HD-12: Aneurysm and AVM

HD-12.1: Intracranial Aneurysms	36
HD-12.2: Arteriovenous Malformations (AVMs) and Related Lesions	37

HD-12.1: Intracranial Aneurysms

- Head CTA (CPT® 70496) or Head MRA (CPT® 70544) can be performed in any of the following clinical scenarios:
 - ◆ Symptoms or signs of cerebral aneurysm, including:
 - “Thunderclap headache” See **HD 11.3: Sudden Onset of Headache**
 - Third nerve palsy with pupillary involvement (pupil-sparing third nerve palsies are not caused by external compression)
 - Suspicion of aneurysm bleed [CT Head or MRI Brain or CSF exam showing evidence of subarachnoid hemorrhage (SAH) or intracerebral hemorrhage]
 - Abnormal Head CT or MRI Brain suggesting possible aneurysm
 - ◆ Screening for High Risk Populations as defined by the following criteria (screening usually begins at age 20 unless unusual circumstances as aneurysms are uncommon in children and adolescents):
 - Positive Family History: Two or more first degree relatives (parent, sibling, or child) with history of cerebral aneurysm or SAH: screening every 5 years beginning at age 20
 - One first degree relative (parent, sibling, or child) with history of cerebral aneurysm or SAH may also have one screening study but risks and benefits should be discussed with patient
 - Autosomal dominant polycystic kidney disease (screening begins at age 20 to 65 and is repeated at ten-year intervals)
 - Aortic coarctation or bicuspid aortic valve
 - Type 4 (Vascular) Ehlers-Danlos Syndrome
 - Marfan’s Syndrome
 - Loeyes-Dietz Syndrome
 - Microcephalic osteodysplastic primordial dwarfism
 - Patients with previous history of SAH or treatment for cerebral aneurysm: continued surveillance and screening every 5 years
 - ◆ Follow up of known cerebral aneurysm
 - Known incidentally discovered aneurysms which have never bled. The optimal interval and duration of recommended follow up in the literature are undefined. The risk of aneurysm rupture is related to size, location (posterior circulation is higher risk), and patient factors including age, sex (higher for female), and history of smoking and hypertension.
 - Follow up at 6 months, 12 months and then annually for up to 5 years or until aneurysm is determined to be stable; and then at decreasing frequency, generally every 5 years unless judged to be at higher risk (see above risk factors).
 - MRI Brain without contrast (CPT® 70551) or with and without (CPT® 70553) may be added if there are new signs, symptoms or clinical findings, or to evaluate giant aneurysm (>2.5 cm).
 - ◆ Follow up of treated aneurysms, clipping or coiling (with or without SAH)
 - Follow up at 3 to 6 month intervals for the first year, then 6 to 12 months for up to 2 years, then annually to ensure that aneurysm is not recanalizing. If stable and occluded at last imaging then follow up surveillance every 5 years. MRA Head without contrast (CPT® 70544), with contrast (CPT® 70545), or

without and with contrast (CPT® 70546) or CTA Head (CPT® 70496) at discretion of the specialist (neurosurgeon)

- Spinal MRI (Cervical, Thoracic, Lumbar (without and with contrast) (CPT® 72156, CPT® 72157, CPT® 72158) is appropriate to evaluate patients with SAH and negative studies for brain aneurysm in whom spinal abnormalities (i.e. AVM) may be suspected as the cause of hemorrhage.

HD-12.2: Arteriovenous Malformations (AVMs) and Related Lesions

- MRI Head without and with contrast (CPT® 70553) or without contrast (CPT® 70551) may be considered in the following clinical scenarios:
 - ◆ AVM is suspected based on a history of SAH.
 - ◆ Screening for:
 - Hereditary hemorrhagic telangiectasia syndrome (Osler Weber Rendu).
 - Familial cavernous malformation: Screening should include MRI Head without or without and with contrast (with gradient echo images).
- In addition to MRI, one Head CTA (CPT® 70496) or Head MRA (CPT® 70544) can be performed for screening. If negative, no further screening studies are indicated
- Head CTA (CPT® 70496) or brain MRA (CPT® 70544 or CPT® 70546) may be considered when known AVM are being evaluated for embolization or surgery
- Repeat advanced imaging with MRI Head without and with contrast (CPT® 70553) or without contrast (CPT® 70551), plus MRA Head (CPT® 70544) or CTA Head (CPT® 70496) may be considered depending on the character of the disease and risk factors, or in the following clinical scenarios:
 - ◆ New hemorrhage episode is likely
 - ◆ Onset or change of seizures
 - ◆ Focal neurological signs
 - ◆ As follow up after treatment (surgery or embolization) as requested by specialists.

Practice Notes

Trauma is the most common reason for subarachnoid hemorrhage. Ruptured berry aneurysm is the most common reason for non-traumatic subarachnoid hemorrhage in adults.

Small aneurysms are present in about 1 to 2% of adults, but very few ever reach a size for which bleeding is a risk (> 5 mm). Small (< 3 to 4 mm) unruptured aneurysms in those with no personal history of SAH have a 0.1% to 0.5% a year rate of bleeding. The risk of cerebral aneurysm with family history ranges from 2% with one first degree relative to 30 to 35% for identical twin or two parents. The risks and benefits of screening these populations need to be considered before advanced imaging.

AVMs most often come to clinical notice either by bleeding or by acting as a seizure focus. They are usually congenital, recognized later in life and have an initial risk of bleeding of 2% per year.

References

1. Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation*. 2000 Oct 31;102(18):2300-2308. Accessed October 17, 2017. <http://circ.ahajournals.org/content/102/18/2300>
2. Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke*. 2009 Mar;40(3):994-1025. Accessed October 17, 2017. <http://stroke.ahajournals.org/content/40/3/994>
3. Vega C, Kwoon JV, and Lavine SD. Intracranial aneurysms: current evidence and clinical practice. *Am Fam Physician*. 2002 Aug 15;66(4):601-609. Accessed October 17, 2017. <http://www.aafp.org/afp/2002/0815/p601.html>
4. Brain Aneurysm Foundation. Early detection and screening. Accessed October 17, 2017. <https://www.bafound.org/about-brain-aneurysms/diagnosis/early-detection-and-screening/>
5. Rozenfeld MN, Ansari SA, Shaibani A, et al. Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms? *Am J Neuroradiol*. 2014 Jan;35(1):3-9. Accessed October 17, 2017. <http://www.ajnr.org/content/35/1/3>
6. Bor ASE, Koffijberg H, Wermer MJH, et al. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. *Neurology*. 2010 May 24; 74(21):1671-1679. Accessed October 17, 2017. <http://www.neurology.org/content/74/21/1671>
7. Schievink WI, Raissi SS, Maya MM, et al. Screening for intracranial aneurysms in patients with bicuspid aortic valve. *Neurology*. 2010 May 4; 74(18):1430-1433. Accessed October 17, 2017. <http://www.neurology.org/content/74/18/1430.short>
8. Vlak MHM, Rinkel GJE, Greebe P, et al. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. *J Neurol Neurosurg Psych*. 2013 Jun; 84(6):619-623. Accessed October 17, 2017. <http://jnnp.bmj.com/content/84/6/619.full>
9. Kelly AG. Unruptured intracranial aneurysms. *Continuum*. 2014 Apr;20(2):387-398. Accessed October 17, 2017. http://journals.lww.com/continuum/Abstract/2014/04000/Unruptured_Intracranial_Aneurysms_Screening_and.15.aspx
10. Thompson BG, Brown RD, Amin-Hanjani S, et al. Guidelines for the management of patients with unruptured intracranial aneurysms. *Stroke*. 2015 Aug; 46(8):2368-2400. Accessed October 17, 2017. <http://stroke.ahajournals.org/content/46/8/2368>
11. Chu LC, Johnson PT, Dietz HC, et al. CT angiographic evaluation of genetic vascular disease: role in detection, staging, and management of complex vascular pathologic conditions. *AJR Am J Roentgenol*. 2014 May; 202(5):1120-1129. Accessed October 17, 2017. <http://www.ajronline.org/doi/full/10.2214/AJR.13.11485>
12. Hishikawa T, Date I, Tokunaga K, et al. Risk of rupture of unruptured cerebral aneurysms in elderly patients. *Neurology*. 2015 Nov 24; 85(21):1879-1885. Accessed October 17, 2017. <http://www.neurology.org/content/85/21/1879.short>
13. Backes, D, Rinkel GJE, Greving JP, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. *Neurology*. 2017 Apr 25;88(17):1600-1606. Accessed October 17, 2017. <http://www.neurology.org/content/88/17/1600.short>
14. Ding D and Ermian N. A model for predicting the growth of unruptured intracranial aneurysms. *Neurology*. 2017 Apr 26;88(17):1594-1595. Accessed October 17, 2017. <http://www.neurology.org/content/88/17/1594.short>

HD-13: Head Trauma

HD-13.1: Head Trauma

40

HD-13.1: Head Trauma

Patients with head trauma are at risk for facial and cervical trauma.

See SP-3: Neck (Cervical Spine) Pain Without/With Neurological Features and Trauma

- Head CT without contrast (CPT® 70450) is the primary imaging modality in patients with acute head trauma and any of the following modified Canadian Criteria:
 - ◆ Taking one anticoagulant or two antiaggregants, (e.g., aspirin and Plavix)
 - ◆ Known platelet or clotting disorder
 - ◆ Renal failure (creatinine > 6)
 - ◆ Glasgow coma scale (GCS) score of less than 15 at 2 hours following injury
 - ◆ > 30 minutes of amnesia
 - ◆ Any “dangerous mechanism of injury” (fall greater than 5 steps down stairs or from height greater than 3 feet; any pedestrian motor vehicle accident or ejection from motor vehicle)
 - ◆ Suspected open skull fracture
 - ◆ Signs of basilar skull fracture
 - ◆ Two or more episodes of vomiting
 - ◆ Patient > 64 years old
- MRI Head without contrast (CPT® 70551) is thereafter used when the clinical findings are not explained by the CT results or to evaluate late effect of brain injury
- Follow-up imaging, MRI or CT, for known subdural hematomas, intracerebral hemorrhage, or contusions can be done at the discretion of ordering specialist

Practice Note

Recent studies have shown that Diffusion tensor MRI tractography may be more sensitive in demonstrating abnormalities such as axonal injury in closed head injury than conventional MRI, but these techniques are best described presently as research tools and their use in routine clinical practice is not determined.

Decisions regarding return to normal activities, including sports, are made based on the clinical status of the patient and repeat imaging is unnecessary.

References

1. Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT head rule for patients with minor head injury. *Lancet*. 2001 May 5;357(9266):1391-1396. Accessed October 17, 2017. Accessed October 17, 2017. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(00\)04561-X/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext)
2. Giza CC, Kutcher JS, Ashwal S, et al. Summary of evidence-based guideline update: evaluation and management of concussion in sports: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2013 Jun 11;80(24):2250-2257. Accessed October 17, 2017. <http://www.neurology.org/content/80/24/2250.full>
3. Wilde EA, McCauley SR, Hunter JV, et al. Diffusion tensor imaging of acute mild traumatic brain injury in adolescents. *Neurology*. 2008 Mar 18;70(12):948-955. Accessed October 17, 2017. <http://www.neurology.org/content/70/12/948.short>
4. Mayer AR, Ling J, Mannell MV, et al. A prospective diffusion tensor imaging study in mild traumatic brain injury. *Neurology*. 2010 Feb 23; 74(8):643-650. Accessed October 17, 2017. <http://www.neurology.org/content/74/8/643.short>

HD-14: CNS Infection

HD-14.1: CNS Infection

42

HD-14.1: CNS Infection

- Signs of intracranial infection include: 1) headaches, seizures or new focal deficits in a setting of fever or elevated white blood cell count (WBC); 2) known infection elsewhere; 3) or immunosuppression. The following studies may be considered for suspected intracranial infection¹⁻⁴ if any of these signs of infection are present:
 - ◆ MRI Head without and with contrast (CPT® 70553) (preferred), **or**
 - ◆ MRI Head without contrast (CPT® 70551), **or**
 - ◆ CT Head without contrast (CPT® 70450), **or**
 - ◆ CT Head without and with contrast (CPT® 70470)

References

1. Jordan JE, Kieffer SA, Booth TN, et al. ACR-ASNR-SPR Parameter for the performance of computed tomography (CT) of the brain. *American College of Radiology (ACR)*. Revised 2015 (Resolution 20). Accessed October 18, 2017. https://www.acr.org/~media/ACR/Documents/PGTS/guidelines/CT_Brain.pdf
2. Wippold FJ, Cornelius RS, Aiken AH, et al. ACR Appropriateness Criteria® Focal neurologic deficit. *American College of Radiology (ACR)*. Date of origin: 2006. Last review date: 2012. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69480/Narrative/>
3. Kastrup O, Wanke I, and Maschke M. Neuroimaging of infections of the central nervous system. *Semin Neurol*. 2008 Sep;28(4):511-522. Accessed October 18, 2017. <https://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1083688>
4. Britton CB. Acquired Immune Deficiency Syndrome. In: *Merritt's Neurology*. 12th ed. Philadelphia, PA: Lippincott; 2010:186-201.
5. Jubelt J. *Spirochete infections, Lyme disease*. In: *Merritt's Neurology*. 12th Ed. Philadelphia, Lippincott; 2010:225-227.
6. Meyerhoff JO, Steele RW, Zaidman GW, et al. Lyme disease. Updated Jun 29, 2017. Accessed October 18, 2017. <http://emedicine.medscape.com/article/330178-overview>.

HD-15: Movement Disorders

HD-15.1: Movement Disorders

44

HD-15.1: Movement Disorders

- The majority of movement disorders are diagnosed based on a clinical diagnosis and do not require imaging. These include:
 - ◆ Typical Parkinson's Disease¹
 - ◆ Essential Tremor or tremors of anxiety or weakness
 - ◆ Restless Leg Syndrome
 - ◆ Tics or spasms which can be duplicated at will
- MRI of the Brain without, or without and with contrast (CPT® 70551 or CPT® 70553) is considered in the following clinical scenarios:
 - ◆ Atypical Parkinsonism because of unusual clinical features (for example, persistent unilateral signs and symptoms, young onset under age of 50, rapid progression), incomplete or uncertain medication responsiveness, or clinical diagnostic uncertainty.¹ These cases should be forwarded for medical director review.
 - ◆ Suspected Huntington Disease¹
 - ◆ Evaluation for surgical treatment of Essential Tremor or Parkinson's disease, including Deep Brain Stimulator placement.
- DAT-SPECT (ioflupane I-123 SPECT) (CPT® 78607) may be considered:
 - ◆ To evaluate patients in whom the diagnosis and differentiation between Parkinson's disease and Essential Tremor remains unclear after evaluation by experts in movement disorders and medication trials.
 - ◆ DAT Scans are not useful for differentiation of subtypes of Parkinson's syndromes, to monitor progression of disease or predict risk of development of disease.

Practice Notes

There is little evidence to support the use of MRA/CTA and PET in the evaluation of movement disorders.²

References

1. Wippold II FJ, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria® Dementia and movement disorders. *American College of Radiology (ACR)*. Date of origin: 1996. Last review date: 2015. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69360/Narrative/>
2. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2006 Apr 11; 66(7):968-975. Accessed October 18, 2017. <http://www.neurology.org/content/66/7/968.short>
3. Gayed I, Joseph U, Fanous M, et al. The impact of DaTscan in the diagnosis of Parkinson's disease. *Clin Nucl Med*. 2015 May;40(5):390-393. Accessed October 18, 2017. http://journals.lww.com/nuclearmed/Fulltext/2015/05000/The_Impact_of_DaTscan_in_the_Diagnosis_of.4.aspx
4. Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinical uncertain Parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. *J Neurol Neurosurg Psychiatry*. 2012 Jun; 83(6):620-628. Accessed October 18, 2017. <http://jnnp.bmj.com/content/83/6/620>
5. Perlmutter JS and Eidelberg D. To scan or not to scan: DaT is the question. *Neurology*. 2012 Mar 6;78(10):688-689. Accessed October 18, 2017. <http://www.neurology.org/content/78/10/688>
6. Bajaj N, Hauser RA, and Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. *J Neurol Neurosurg Psychiatry*. 2013 Nov;84(11):1288-1295. Accessed October 18, 2017. <http://jnnp.bmj.com/content/84/11/1288>
7. Seifert KD and Wiener JI. The impact of DaT scan on the diagnosis and management of movement disorders: a retrospective study. *Am J Neurodegener Dis*. 2013;2(1) 29-34. Accessed October 18, 2017. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601468/>
8. de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. *Neurology*. 2012 Mar 6; 78(10):696-701. Accessed October 18, 2017. <http://www.neurology.org/content/78/10/696.short>
9. Hess CW and Okun MS. Diagnosing Parkinson Disease. *Continuum*. 2016 Aug; 22(4):1047-1063. Accessed October 18, 2017. http://journals.lww.com/continuum/Abstract/2016/08000/Diagnosing_Parkinson_Disease.6.aspx
10. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders. *Clin Nucl Med*. 2017 Nov;42(11):847-852. Accessed November 28, 2017. <https://insights.ovid.com/crossref?an=00003072-201711000-00006>.
11. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? *Neurodegener Dis*. 2015;15(2):81-86. Accessed November 28, 2017. <https://www.karger.com/Article/FullText/370116>.

HD-16: Multiple Sclerosis (MS) and Related Conditions

HD-16.1: Multiple Sclerosis

47

HD-16.1: Multiple Sclerosis (MS)

- MRI Head without and with contrast (CPT® 70553) and MRI Cervical and Thoracic spine without and with (CPT® 72156 and CPT® 72157) use in these clinical scenarios requires¹ clinical suspicion based on recurrent episodes of variable neurological signs and symptoms or clinically isolated syndromes and² the baseline exclusion of appropriate alternative conditions that can mimic MS¹⁻⁴
 - ◆ An Orbital MRI without and with contrast (CPT® 70543) may be considered if optic neuritis is suspected, in addition to the above scenario⁴
 - ◆ If a non-contrast study shows incidental evidence of possible demyelinating disease, repeat with MRI Brain with contrast (CPT® 70552) may be approved within 2 weeks of previous non-contrast study as the presence of enhancing lesions may be helpful in confirming the diagnosis
 - If non-contrast study was performed more than 2 weeks prior to the request for repeat imaging, an MRI Brain with and without contrast (CPT® 70553) is appropriate.
 - ◆ If the diagnosis is still equivocal after initial screening repeat studies in 3 to 6 months may be performed
 - ◆ Evidence does not support the use of 3T MRI as being more effective than 1.5T units for diagnosis or follow up of MS. Requests for repeat imaging should meet guidelines for timeliness as noted within these guidelines regardless of type of facility requested
- MRI Lumbar spine usually is not needed since Cervical and Thoracic studies will usually visualize the entire spinal cord
- Repeat Brain and/or Spine imaging in an established patient may be considered in the following scenarios:
 - ◆ New episode of neurological deficit⁴
 - ◆ Baseline, in 3 to 6 months and then annually when instituting or maintaining immune-modulating agents and when changing therapy⁴
 - ◆ Symptoms suggestive of Progressive Multifocal Leukoencephalopathy (PML) during Tysabri therapy.⁵
 - Screening for patients on natalizumab (Tysabri) or other drugs with risk of PML (Progressive Multifocal Leukoencephalopathy)
 - If Anti-JCV antibody negative: MRI Brain annually
 - If Anti-JCV antibody positive: MRI every 6 months
 - If Anti-JCV antibody positive and titer > 1.5, and > two years on treatment: MRI Brain may be performed every 3 months.
 - ◆ Repeat imaging requests for MRI without contrast for follow up may be approved when requested by a specialist
- Family members need not be screened, unless they exhibit suspicious signs or symptoms suggestive of MS.

Practice Notes

Multiple Sclerosis is common and variable with more women affected and at a younger age than men. MS tends to be relapsing-remitting (improves between episodes), relapsing-progressive (worsens with attacks) and chronic progressive (gradual and steady).

MS is a clinical diagnosis, traditionally recognized by “lesions dispersed in time and space,” which means involvement of different areas of the neuraxis at different times.”

Screening based on family history of MS is not supported by the peer-reviewed evidence.

Sagittal MRI of the Spinal cord with phased array detector coil (CPT® 72156 or CPT® 72157) is an alternative spinal imaging.

References

1. Gordon JM. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. *Neurology*. 2004 Mar 9; 62(5):838. Accessed October 18, 2017. <http://www.neurology.org/content/62/5/838.1.short>
2. Scott TF and Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2011 Dec 13; 77(24):2128-2134. Accessed October 18, 2017. <http://www.neurology.org/content/77/24/2128.full>
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011 Feb; 69(2):292-302. Accessed October 18, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/ana.22366/full>
4. Lövblad K-O, Anzalone N, Dörfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. *Am J Neuroradiol*. 2010 Jun; 31(6):983-989. Accessed October 18, 2017. <http://www.ajnr.org/content/31/6/983>
5. FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). Originally issued February 5, 2010. Update issued April 22, 2011. U S Food and Drug Administration Home Page. Accessed October 18, 2017. <https://www.fda.gov/Drugs/DrugSafety/ucm288186.htm>
6. Traboulsee A, Simon JH, Stone L, et al. Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. *Am J Neuroradiol*. 2016 Mar; 37(3):397-401. Accessed October 18, 2017. <http://www.ajnr.org/content/37/3/394>
7. Mcguigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. *Journal of Neurology, Neurosurgery & Psychiatry*. 2015.
8. Hagens MH, Burggraaff J, Kilsdonk ID, et al. Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. *Neurology*. 2018;91(3):249-257.

HD-17: Papilledema/Pseudotumor Cerebri
HD-17.1: Papilledema/Pseudotumor Cerebri 50

HD-17.1: Papilledema/Pseudotumor Cerebri

- MRI Head without and with contrast (CPT® 70553) can be considered when there is suspected elevated intracranial pressure, such as with pseudotumor cerebri (benign intracranial hypertension) and papilledema, to exclude cerebral mass lesions, obstructive hydrocephalus, or occult meningeal disease.
 - ◆ Orbital MRI (CPT® 70543) or Orbit CT without and with (CPT® 70482) may be considered if there is concern for orbital pseudotumor or a primary bilateral orbital disorder.
 - ◆ Repeat imaging may be considered to evaluate either:
 - Shunt dysfunction in those patients who have had ventriculoperitoneal (VP) or lumboperitoneal (LP) shunts
 - Clinical deterioration
 - ◆ MRA Head without contrast or CTA Head without and with contrast can be approved for papilledema with suspected venous sinus thrombosis.
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only **one** CPT® code should be used to report both procedures
 - ◆ See **HD-1.5: General Guidelines - CT and MR Angiography: (CTA and MRA)** for information regarding contrast in MRA.

Reference

1. Mokri B. Spontaneous intracranial hypotension spontaneous CSF Leaks. *Headache Currents*. 2005 Jan; 2(1):11-22. Accessed October 18, 2017. <http://onlinelibrary.wiley.com/doi/10.1111/j.1743-5013.2005.20102.x/abstract>

HD-18: Paresthesias

HD-18.1: Paresthesias

52

HD-18.1: Paresthesias

Requests will be sent for Medical Director review. Paresthesia(s) (localized numbness and tingling) are symptoms of a local (nerve entrapment for example), regional (Multiple Sclerosis for example) or central (stroke for example) disorder.^{1,2} Advanced imaging can be considered initially, based on the highest suspicion disorder, according to these guidelines.^{1,2}

References

1. Paresthesia Information Page. National Institute of Neurological Disorders and Stroke. Accessed October 18, 2017. <https://www.ninds.nih.gov/Disorders/All-Disorders/Paresthesia-Information-Page>.
2. Paresthesia. ReedGroup® MDGuidelines. Accessed October 18, 2017. <http://www.mdguidelines.com/paresthesia>.

HD-19: Pituitary

HD-19.1: Pituitary	54
HD 19.2: Additional Imaging	56

HD-19.1: Pituitary

- Endocrine laboratory studies should be performed prior to considering advanced imaging, including Prolactin levels; thyroid function levels should also be checked to evaluate for untreated or inadequately treated hypothyroidism as a cause of hyperprolactinemia and pituitary hyperplasia
 - ◆ Lab results should be recent, within 6 weeks of the request.
- Pituitary imaging is primarily performed with MRI Head without and with contrast (CPT® 70553):
 - ◆ MRI Orbit, Face, Neck (CPT® 70543) or CT Head without and with contrast (CPT® 70470) are alternatives
 - ◆ CT Head without contrast (CPT® 70450) or without and with contrast (CPT® 70470) and/or CT Maxillofacial without contrast (CPT® 70486) is occasionally used in addition to MRI to visualize perisellar bony structures in the preoperative evaluation of certain sellar tumors and for preoperative planning for transphenoidal approaches
- Incidentally found lesions on other studies:
 - ◆ If a pituitary abnormality is reported incidentally on a MRI Brain or CT Brain performed for other reasons, a follow-up dedicated pituitary study may be obtained (MRI Brain without and with contrast CPT® 70553 or MRI Orbit/Face/Neck CPT® 70543. CPT® 70553 covers both brain and dedicated pituitary if performed at the same time; no additional CPT® codes are needed); further evaluation and subsequent imaging dependent on specific imaging and biochemical laboratory evaluation findings.

Pituitary Imaging

Microadenoma (< 10 mm)		
Indication	Initial Imaging	Repeat Imaging
Acromegaly**** (Elevated IGF-1 confirmed by lack of suppression of growth hormone on glucose suppression testing, with or without acromegaly)	MRI Head without and with contrast (CPT® 70553)	<ul style="list-style-type: none"> ➤ MRI Brain without and with contrast (CPT® 70553) <ul style="list-style-type: none"> ◆ At least 12 weeks after surgery to evaluate for residual tumor ◆ If treated with Pegvisomant, 6 to 12 months after treatment initiated, then annually if stable ◆ If hormone levels increase or neurological findings appear
Microadenoma: Nonfunctioning, unexplained pituitary asymmetries, and incidentally found small tumors (< 10 mm)	MRI Head without contrast and with contrast (CPT® 70553)	<ul style="list-style-type: none"> ➤ MRI Head without contrast and with contrast (CPT® 70553) at: <ul style="list-style-type: none"> ◆ 6 and 12 months, then yearly for 3 years if stable. After 3 years, then every other year for the next 6 years, then every 5 years if stable
Rathke's cleft cyst/Simple cyst	MRI Head without and with contrast (CPT® 70553)	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast (CPT® 70553) in one year; if stable and without mass effect or invasion into surrounding structures, no further imaging is required.

<p>Prolactinomas*</p>	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast (CPT® 70553) with: <ul style="list-style-type: none"> ◆ Unexplained elevated prolactin level above normal reference range ◆ After initial start of dopamine agonist therapy, repeat MRI in 1 year (or in 3 months if macroprolactinoma), also repeat if prolactin levels continue to rise while on dopaminergic agents, or if new symptoms emerge (e.g., galactorrhea, visual disturbances, headaches, or other hormonal disorders occur) ◆ Image after 2 years of dopamine agonist treatment for those who are being considered for discontinuation of treatment due to remission ◆ After 2 years of dopamine agonist therapy, for those who have achieved normal Prolactin levels and no visible tumor remnant, and for whom dopamine agonists have been discontinued or tapered, image if prolactin level increases above normal range. ◆ Galactorrhea/nipple discharge with normal prolactin and thyroid function levels: See BR-7: Nipple Discharge/Galactorrhea 	
<p>TSH, FSH, ACTH and LH producing</p>	<p>MRI Head without and with contrast (CPT® 70553) when hormone levels are inappropriately elevated.</p>	
<p>Male Hypogonadism</p>	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast (CPT® 70553) if <ul style="list-style-type: none"> ◆ Severe secondary hypogonadism (morning serum testosterone level < 150 ng/dl and low or normal LH and FSH levels) ◆ Serum, free, or bioavailable morning testosterone level below normal range and low or normal LH and FSH levels accompanied by one of the following: ◆ Panhypopituitarism, hyperprolactinemia, symptoms or signs of tumor mass effect (e.g. headache, visual impairment, or visual field deficit), *****suspected alterations in sex hormone binding globulin (SHBG) 	
<p>Panhypopituitarism</p>	<p>MRI Head without and with contrast (CPT® 70553)</p>	
<p>ADH Abnormalities</p>		
<p>Indication</p>	<p>Initial Imaging</p>	<p>Repeat Imaging for Non-Operative Care</p>
<p>Diabetes Insipidus (DI)</p>	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast (CPT® 70553) if: <ul style="list-style-type: none"> ◆ Laboratory testing consistent with DI (serum osmolality should be high and urine osmolality should be low) and etiology uncertain 	<p>NA</p>
<p>Syndrome of Inappropriate ADH (SIADH)</p>	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast (CPT® 70553) if: <ul style="list-style-type: none"> ◆ Etiology remains uncertain or is thought to be in the nervous system; ◆ Urine osmolality should be high and serum osmolality low 	<p>NA</p>

Macroadenoma (> 10 mm) (if not surgically removed and normal hormonal testing)	MRI Head without and with contrast (CPT® 70553)	<ul style="list-style-type: none"> ➤ MRI Head without and with contrast(CPT® 70553) every: <ul style="list-style-type: none"> ◆ 6 months for the first year; then ◆ Annually for 5 years (longer if craniopharyngiomas); ◆ Every 6 months if treatment is deferred.
Other Pituitary Region Tumors**	Evaluation may require CT in addition to MRI to evaluate for hyperostosis. Requests will be sent for Medical Director review.	
Enlarged/Empty Sella Turcica***	<ul style="list-style-type: none"> ➤ Head CT without and with contrast (CPT® 70470) or, MRI Head without and with contrast (CPT® 70553) to: <ul style="list-style-type: none"> ◆ Exclude residual pituitary tumor, and ◆ To assess the position of the chiasm since herniation into the sella, causes Chiasmatic-type visual loss 	MRI without and with contrast (CPT® 70553) 1 to 5 years after the initial study can be performed.

Practice Notes

Normal ranges may vary among different labs.

FSH

Male: 5-15 mIU/mL

Female: Follicular or luteal phase 5-20 mIU/mL, Midcycle peak 30-50 mIU/mL,

Postmenopausal >35 mIU/mL

LH

Male: 3-15 mIU/mL

Female: Follicular or luteal phase 5-22 mIU/mL, Midcycle peak 30-250 mIU/mL,

Postmenopausal >30 mIU/mL

Testosterone

Male 300-1200 ng/dL

Female 20-75 ng/dL

TSH

0.5-5 µIU/mL

GH

After oral glucose, <2 ng/mL

Osmolality

Urine 38-1400 mosm/kg H₂O

Serum 275-295 mosm/kg H₂O

HD 19.2: Additional Imaging

- Post-operatively, follow-up pituitary imaging is generally done at the discretion of the neurosurgeon, usually at 4 months and then at one year if stable
- For those who are treatment resistant on standard or maximal tolerable doses of dopamine agonist therapy (e.g. visible tumor remnant or persistent elevation of Prolactin levels) and who will not be treated with surgery/radiation, continue imaging periodically as per microadenoma or macroadenoma guidelines, accordingly
- For those in whom treatment is discontinued at the onset of menopause, continue imaging periodically as per microadenoma or macroadenoma guidelines, accordingly

Practice Notes

***Prolactinoma Note:** Most common of the secreting Microadenoma (> 50 *To establish the diagnosis of hyperprolactinemia, a **single** measurement of serum prolactin is recommended; a level above the upper limit of normal confirms the diagnosis as long as the serum sample was obtained without excessive venipuncture stress.* Long-term or inadequately treated primary hypothyroidism can cause pituitary hyperplasia that may mimic a pituitary tumor and therefore thyroid functions should also be checked to evaluate for untreated or inadequately treated hypothyroidism as a cause of hyperprolactinemia and pituitary hyperplasia. Routine surveillance during pregnancy is not recommended due to risk to fetus. Repeat imaging with MRI without gadolinium is performed for new or worsening symptoms, such as headaches or visual symptoms. *In women with microprolactinomas, it may be possible to discontinue dopaminergic therapy when menopause occurs. Surveillance for increasing size of the pituitary tumor should continue on a periodic basis.

****Other Pituitary Region Tumor Notes:** Craniopharyngiomas arise in the parasellar area. About 10% of meningiomas arise in this area.

*****Enlarged/Empty Sella Turcica Notes:** An enlarged sella turcica without evident tumor is an incidental finding on MRI Head or CT Head from a defect in the dural diaphragm of the sella (especially if there is elevated intracranial pressure from another cause), pituitary surgery, or as a result of a pituitary tumor which has expanded the sella and then infarcted (pituitary apoplexy).

******Acromegaly:** Rarely, biochemically confirmed acromegaly with a normal pituitary gland on MRI may occur. Somatostatin receptor scintigraphy (Octreoscan) of thorax and abdomen and growth hormone-releasing hormone (GHRH) level may be considered to evaluate ectopically located disease.

*******Male Hypogonadism:** Certain conditions can cause alterations in sex hormone-binding globulin (SHBG) which can impact testosterone levels. Free or bioavailable testosterone concentrations should be measured when total testosterone concentrations are close to the lower limit of the normal range and when altered SHBG levels are suspected (e.g. moderate obesity, nephrotic syndrome, hypo- and hyperthyroidism, use of glucocorticoids, progestins, estrogens, and androgenic steroids, anticonvulsants, acromegaly, diabetes mellitus, aging, HIV disease, liver cirrhosis,

hepatitis). Note that if the initial testosterone level is found to be low, reversible illness, drugs and nutritional deficiency should be excluded as a cause prior to repeating testosterone level. LH and FSH should be obtained to evaluate for secondary (central) hypogonadism, once low testosterone level is confirmed.

References

1. Schlechte JA. Clinical practice. Prolactinoma. *N Engl J Med*. 2003 Nov 20; 349(21):2035-2041. Accessed October 18, 2017. <http://www.nejm.org/doi/full/10.1056/NEJMcp025334>
2. Ciric I. Long-term management and outcome for pituitary tumors. *Neurosurg Clin N Am*. 2003 Jan; 14(1):167-171. Accessed October 18, 2017. [http://www.neurosurgery.theclinics.com/article/S1042-3680\(02\)00030-X/fulltext](http://www.neurosurgery.theclinics.com/article/S1042-3680(02)00030-X/fulltext)
3. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. *Endocr Pract*. 2002; 8(6):439-456. Accessed October 18, 2017. <http://journals.aace.com/doi/pdf/10.4158/EP.8.6.439>
4. Katznelson L, Laws Jr, ER, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014 Nov;99(11):3933-3951. Accessed October 18, 2017. <https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2014-2700>
5. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2011 Feb;96(2):273-288. Accessed October 18, 2017. <https://academic.oup.com/jcem/article/96/2/273/2709487/Diagnosis-and-Treatment-of-Hyperprolactinemia-An>
6. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society practice guideline. *J Clin Endocrinol Metab*. 2011 Apr;96(4):894-904. Accessed October 18, 2017. <https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2010-1048>
7. Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. *CMAJ*. 2003 Sep 16; 169(6):575-581. Accessed October 18, 2017. <http://www.cmaj.ca/content/169/6/575.full>
8. Dekkers JM, Pereira AM, and Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. *J Clin Endocrinol Metabol*. 2008 Oct;93(10):3717–3726. Accessed October 18, 2017. <https://academic.oup.com/jcem/article/93/10/3717/2627275/Treatment-and-Follow-Up-of-Clinically>
9. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. *J Clin Endocrinol Metabol*. 2010 Jun;95(6): 2536–2559. Accessed October 18, 2017. <https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2009-2354>
10. Hoang JK, Hoffman AR, González RG, et al. Management of Incidental Pituitary Findings on CT, MRI, and 18 F-Fluorodeoxyglucose PET: A White Paper of the ACR Incidental Findings Committee. *Journal of the American College of Radiology*. 2018;15(7):966-972.
11. Ludlam W. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. *Yearbook of Endocrinology*. 2011;2011:325-326.

HD-20: Scalp and Skull Lesions

HD-20.1: Scalp and Skull Lesions

60

HD-20.1: Scalp and Skull Lesions

The majority of these are benign soft tissue or bony lesions easily defined by physical examination or with skull x-rays or ultrasound.

- CT Head without or without and with contrast (CPT® 70450 or CPT® 70470) is appropriate for the following scenarios:
 - ◆ Any lesion on physician examination and skull x-ray or ultrasound which is not clearly benign.
 - ◆ Langerhans' cell histiocytosis, myeloma, and metastatic cancer, when symptoms suggest bony lesions.
- MRI Head without contrast (CPT® 70551) or with and without contrast (CPT® 70553) may be considered if there is concern for intracranial extension.

HD-21: Stroke/TIA

HD-21.1: Stroke/TIA	62
HD-21.2: Venous Infarcts	62

HD-21.1: Stroke/TIA

- **One** from each of the following procedures can be considered for the initial occurrence or repeat episodes of TIA, stroke¹⁻⁴ or Transient Global Amnesia⁵
 - ◆ CT Head without contrast (CPT® 70450) or CT Head without and with contrast (CPT® 70470) **or** MRI Head without and with contrast (CPT® 70553) **or** MRI Head without contrast (CPT® 70551)
 - MRI is preferred with later presentation for evaluation and can be considered after an initial CT head¹⁻⁴
 - ◆ Duplex ultrasound of the Carotid Arteries (CPT® 93880) **or** MRA Neck without contrast (CPT® 70547) **or** MRA Neck with contrast (CPT® 70548) **or** MRA Neck without and with contrast (CPT® 70549) **or** Neck CTA (CPT® 70498); **and** MRA Head without contrast (CPT® 70544) or CTA Head (CPT® 70496)
- MRA Head without contrast (CPT® 70544) or CTA Head with contrast (CPT® 70496) may be considered in addition to the above in the following clinical scenarios:
 - ◆ Vertebrobasilar stroke (vertigo associated with diplopia, dysarthria, bifacial numbness or ataxia)¹⁻⁴
 - ◆ Suspected carotid or vertebral artery dissections.²⁻⁴ Risks may include premature stroke (under age 50), head or neck trauma, fibromuscular dysplasia, Ehlers-Danlos syndrome, and chiropractic neck manipulation
 - Repeat imaging as determined by a specialist.
 - ◆ Suspected venous infarcts [as MRV (CPT® 70544) or CTV (CPT® 70496)] if identified on CT/MRI Head⁶
- MRA Neck without and with contrast (CPT® 70549) is reserved for evaluation of possible or known arterial dissection
- Transcranial Doppler Studies may also be performed for patients with documented stroke or TIA (See **HD-24.8: Transcranial Doppler (CPT® 93886)**)

HD-21.2: Venous Infarcts

- MRV (CPT® 70544) or CTV (CPT® 70496) and MRI Head without contrast (CPT® 70551) are appropriate in the following scenarios:
 - ◆ Intracranial hypertension with headache, vomiting and papilledema from venous sinus thrombosis
 - ◆ Venous infarction is identified on MRI Head or CT Head
 - ◆ Women with postpartum stroke or postpartum papilledema
 - ◆ Children or young adults who present with a stroke in which headache and seizures are prominent features, or who are known to have an intrinsic system clotting disorder

Practice Notes

Transient Global Amnesia is the "...sudden onset of transient inability to retain new information and to recall previous events for a variable period of time, generally occurring in middle-aged or elderly patients formerly in good health and without significant cardiac or cerebrovascular disease..."⁵

References

1. Salmela MB, Mortazavi S, Jagadeesan BD, et al. ACR Appropriateness Criteria® Cerebrovascular disease. *American College of Radiology (ACR)*. Date of origin: 1996. Last review date: 2016. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69478/Narrative/>
2. Latchaw RE, Alberts MJ, Lev MH, et al. Recommendations for imaging of acute ischemic stroke. *Stroke*. 2009; 40(11):3646-3678. Accessed October 18, 2017. <http://stroke.ahajournals.org/content/40/11/3646>
3. Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. *Am J Neuroradiol*. 2013; 34(11):E117-E127. Accessed October 18, 2017. <http://www.ajnr.org/content/34/11/E117>
4. Bernheisel CR, Schlaudecker JD, and Leopold K. Subacute management of ischemic stroke. *Am Fam Physician*. 2011 Dec; 84(12):1383-1388. Accessed October 18, 2017. <http://www.aafp.org/afp/2011/1215/p1383.html>
5. Zorzon M, Antonutti L, Masè G, et al. Transient global amnesia and transient ischemic attack: natural history, vascular risk factors, and associated conditions. *Stroke*. 1995 Sep; 26(9):1536-1542. Accessed October 18, 2017. <http://stroke.ahajournals.org/content/26/9/1536>
6. Kovacs MJ. Letter by Kovacs regarding article, "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association". *Stroke*. 2011 July; 42(7):e408. Accessed October 18, 2017. <http://stroke.ahajournals.org/content/42/7/e408>
7. Rowland LP, Pedley TA, and Merritt HH. *Merritt's Neurology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
8. Ardila A and Farlow M. Transient global amnesia. *Neurology MedLink*. Originally released September 18, 1995; last updated May 22, 2015; expires May 27, 2018. Accessed October 18, 2017. http://www.medlink.com/article/transient_global_amnesia
9. Stam J. Thrombosis of the cerebral veins and sinuses. *N Engl J Med*. 2005 Apr 28; 352(17):1791-1798. Accessed October 18, 2017. http://www.nejm.org/doi/full/10.1056/NEJMra042354?keytype=tf_ipsecsha&ijkey=eb55b8e59b12c7b82ee7d079f1ecca68a777bf7c
10. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. *N Engl J Med* 2001 Mar 22; 344(12):898-906. Accessed October 18, 2017. http://www.nejm.org/doi/full/10.1056/NEJM200103223441206?siteid=nejm&keytype=ref&ijkey=8mgrL_tMkkzwQs
11. Arnold M and Bousser M-G. Carotid and vertebral artery dissection. *Pract Neurol* 2005 Apr; 5(2):100-109. Accessed October 18, 2017. <http://pn.bmj.com/content/practneurol/5/2/100.full.pdf>

HD-22: Cerebral Vasculitis

HD-22.1: Cerebral Vasculitis

65

HD-22.1: Cerebral Vasculitis

- MRI Head without and with contrast (CPT® 70553) is considered when CNS vasculitis is suspected
 - ◆ MRA Head without and with contrast (CPT® 70546) and MRA Neck without or with contrast (CPT® 70549); CTA³ may be considered in addition to MRI

Practice Notes

Classification of vasculitides based on vessel size adapted from Joseph.¹ MRA and CTA are useful for the evaluation of the large proximal arteries; evaluation of a possible small vessel vasculitis may be beyond the resolution of routine Head MRA and CTA. However, other abnormalities, such as atherosclerotic disease, arterial dissection, Moyamoya disease, or reversible cerebral vasoconstriction may be demonstrated. Conventional angiogram is superior to MRA and CTA in demonstrating abnormalities in smaller vessels and is considered the “gold standard” in the evaluation of primary small vessel CNS vasculitis.

Dominant Vessel Involved	Primary	Secondary
Large arteries	<ul style="list-style-type: none"> ➤ Giant cell arteritis ➤ Takayasu’s arteritis 	Aortitis with rheumatoid disease; Infection (e.g. syphilis)
Medium Arteries	<ul style="list-style-type: none"> ➤ Classical polyarteritis nodosa ➤ Kawasaki disease 	Infection (e.g. hepatitis B)
Small vessels and medium arteries	<ul style="list-style-type: none"> ➤ Wegener’s granulomatosis ➤ Churg–Strauss syndrome ➤ Microscopic polyangiitis 	Vasculitis with rheumatoid disease, systemic lupus erythematosus, Sjögren’s syndrome, drugs, infection (e.g. HIV)
Small vessels	<ul style="list-style-type: none"> ➤ Henoch-Schönlein purpura ➤ Essential cryoglobulinaemia ➤ Cutaneous leukocytoclastic vasculitis 	Drugs (e.g. sulphonamides, etc.) Infection (e.g. hepatitis C)

References

1. Joseph FG and Scolding NJ. Cerebral vasculitis: a practical approach. *Pract Neurol*. 2002 Apr;2(2):80-93. Accessed October 18, 2017. <http://pn.bmj.com/content/practneurol/2/2/80.full.pdf>
2. Turski PA, Mirsky DM, Booth TN, et al. ACR-ASNR-SNIS-SPR practice guideline for the performance of cervicocerebral magnetic resonance angiography (MRA). *American College of Radiology (ACR)*. 2015 (Resolution 10). Accessed October 18, 2017. https://www.acr.org/~media/ACR/Documents/PGTS/guidelines/Cervicocerebral_MRA.pdf.

HD-23: Dizziness, Vertigo and Syncope

HD-23.1: Dizziness, Vertigo, and Syncope

67

HD-23.1: Dizziness, Vertigo, and Syncope

- The initial components in the evaluation of false sensations of balance or motion include obtaining a patient history and performing a physical examination that can assist in diagnosis. These include the elimination of inciting factors^{1,2}
- Evaluation of arterial blood flow (Carotid Doppler, transcranial Doppler, Neck and Head MRA/CTA), CT Head and MRI Head are not indicated unless a primary neurological cause of transient loss of consciousness is suspected based on the presence of neurological symptoms and signs indicating an intracranial disorder. Neurological testing is not indicated for patients with uncomplicated syncope
- Prior to advanced imaging, the minimum initial evaluation should include the following:
 - ◆ A detailed description of the symptoms
 - ◆ Orthostatic blood pressure^{1,2}
 - ◆ Dix-Hallpike maneuver or other positional testing^{1,2}
 - ◆ Nystagmus examination^{1,2}
 - ◆ Any one Gait examination, including Romberg^{1,2}
 - ◆ Psychiatric evaluation including for anxiety or panic disorders (if suspected)^{1,2}
 - ◆ Hearing testing (if associated with hearing loss) to determine if conductive, sensorineural, or mixed⁵
 - ◆ Vision examination¹
- CT Temporal bone without contrast (CPT® 70480) may be considered in addition to the MRI evaluation if concern for trauma, superior canal dehiscence or other bony abnormalities
- MRI Head with attention to internal auditory canal without and with contrast (CPT® 70553) or without contrast (CPT® 70551; limited study CPT® 70540 or CPT® 70543)^{3,5} can be considered when the initial evaluation reveals:
 - ◆ Any associated neurological signs or symptoms²
 - Cerebrovascular symptoms of TIA or CVA²
 - Examples include drop attacks, seizures, coincident headache, ataxia, aura or focal neurological findings
 - ◆ Equivocal or unusual nystagmus findings, including direction changing or persistent downbeat nystagmus^{2,4}
 - ◆ Absent head thrust sign²
 - ◆ Short duration (minutes) recurrent attacks²
 - CT Temporal bone without contrast (CPT® 70480) may be considered in addition to the MRI evaluation⁵
 - ◆ Hearing loss associated with
 - Progressive unilateral hearing loss³
 - Sensorineural⁵
 - Conductive:⁵ CT Temporal bone without contrast (CPT® 70480) may be considered in addition to the MRI evaluation
 - Congenital or total hearing loss:⁵ CT Temporal bone without contrast (CPT® 70480) may be considered in addition to the MRI evaluation

- Pre-surgical planning or cochlear implant candidate:⁵ CT Temporal bone without contrast (CPT[®] 70480) may be considered in addition to the MRI evaluation
- ◆ Features atypical for benign positional vertigo, which may include abnormal cranial nerve findings, visual disturbances, and severe headache⁴
- ◆ Central vertigo
- ◆ See **HD-21: Stroke/TIA**

References

1. Post RE and Dickerson LM. Dizziness: a diagnostic approach. *Am Fam Physician*. 2010 Aug 15;82(4):361-368. Accessed October 18, 2017. <http://www.aafp.org/afp/2010/0815/p361.html>
2. Kerber KA and Baloh RW. The evaluation of a patient with dizziness. *Neurol Clin Pract*. 2011 Dec; 1(1):24-33. Accessed October 18, 2017. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613190/>
3. Labuguen RH. Initial evaluation of vertigo. *Am Fam Physician*. 2006 Jan 15; 73(2):244-251. Accessed October 18, 2017. <http://www.aafp.org/afp/2006/0115/p244.html>
4. Bhattacharrya N, Baugh RF, Orvidas L, et al. Clinical practice guideline: benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg*. 2008 Nov;139(5 Suppl 4):S47-S81. Accessed October 18, 2017. <http://journals.sagepub.com/doi/10.1016/j.otohns.2008.08.022>
5. Angtuaco EJ, Wippold II FJ, Cornelius RS, et al. ACR Appropriateness Criteria[®] Hearing loss and/or vertigo. *American College of Radiology (ACR)*. Date of origin: 1996. Last review date: 2013. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69488/Narrative/>
6. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009): the task force for the diagnosis and management of syncope of the European society of cardiology (ESC). *Eur Heart J*. 2009;30(21):2631-2671. Accessed October 18, 2017. <https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehp298>
7. Minor LB. Superior canal dehiscence syndrome. *Am J Otol*. 2000 Jan-Feb;21(1):9-19. Accessed October 18, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/10651428>
8. Brignole M. Diagnosis and treatment of syncope. *Heart*. 2007 Jan;93(1):130-136. Accessed October 18, 2017. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861366/>
9. Shukla GJ and Zimetbaum PJ. Syncope. *Circulation*. 2006 Apr 25;113(16):e715-e717. Accessed October 18, 2017. <http://circ.ahajournals.org/content/113/16/e715>
10. Cheshire, W. Syncope. *Continuum*. 2017 Apr;23(2): 335-358. Accessed October 18, 2017. <http://journals.lww.com/continuum/Abstract/2017/04000/Syncope.6.aspx>

HD-24: Other Imaging Studies

HD-24.1: Treatment Planning	70
HD-24.2: Functional MRI (f-MRI)	70
HD-24.3: Magnetic Resonance Spectroscopy (MRS)	70
HD-24.4: CSF Flow Imaging	71
HD-24.5: CT or MRI Perfusion	71
HD-24.6: Magnetic Resonance Neurography (MRN)	71
HD-24.7: Cone Beam Computed Tomography (CBCT)	71
HD-24.8: Transcranial Doppler (CPT®93886)	71

Some payers may consider these techniques investigational, and their coverage policies may take precedence over eviCore's guidelines.

HD-24.1: Treatment Planning

- Advanced imaging (CT and MRI) performed for the purpose of surgical planning and navigation should be coded as Unlisted CT (CPT® 76497) or Unlisted MRI (CPT® 76498)
 - ◆ All requests for imaging to be performed for the purpose of surgical planning and navigation should be forwarded to Medical Director Review
- Requests may refer to systems such as Brainlab or Stealth imaging procedures
- This includes requests for intraoperative studies (inpatient studies do not require preauthorization)
- Some health plans do not require prior authorization for the unlisted codes for treatment planning, and eviCore is not contracted to review them. Please refer to individual health plan policy.

HD-24.2: Functional MRI (f-MRI)

- f-MRI is useful in pre-operative scenarios to define the “eloquent” areas of brain
- The ordering physician must be a neurosurgeon or radiation oncologist. All other requests should be sent for MD review. It must be evident that brain surgery is planned, and that f-MRI is being performed to avoid the language centers, or other processing centers, of the brain
- f-MRI can be approved with PET Brain in epilepsy surgery planning
- Procedure codes for functional MRI:
 - ◆ CPT® 70554 MRI Head, functional MRI, including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration
 - ◆ CPT® 70555 MRI Head, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing

HD-24.3: Magnetic Resonance Spectroscopy (MRS)

- All requests for MRS (CPT® 76390) will be forwarded for Medical Director review
- MRS involves analysis of the levels of certain chemicals in a pre-selected voxels (small regions) on an MRI scan done at the same time
- MRS is evaluated on a case-by-case basis, and may be considered:
 - ◆ Distinguish recurrent brain tumor from radiation necrosis as an alternative to PET (CPT® 78608)
 - ◆ Diagnosis of certain rare inborn errors of metabolism affecting the CNS (primarily pediatric patients)

HD-24.4: CSF Flow Imaging

- This is generally imaged as a part of a head MRI study. It is not coded separately for preoperative evaluation of hydrocephalus and Chiari syndrome, with either features of hydrocephalus or syrinx
- There is no specific or unique procedure code for this study; it is done as a special sequence of a routine MRI head without contrast (CPT® 70551)
- If not previously performed as part of recent study, a second study for the purpose of evaluating CSF flow may be performed

HD-24.5: CT or MRI Perfusion

- Performed as part of a CT Head or MRI Head examination in the evaluation of patients with very new strokes or brain tumors.
- Category III 0042T - “cerebral perfusion analysis using CT”. The study is generally limited to evaluation of acute stroke (< 6 hours). Other indications are usually regarded as investigational and experimental. Individual health plan policies should be confirmed.
- There is no specific CPT® code for MRI Perfusion. Perfusion weighted images are obtained with contrast and are not coded separately from a contrasted MRI Head examination. If MRI Head without and with contrast is approved, no additional CPT® codes are necessary or appropriate to perform MRI perfusion.

HD-24.6: Magnetic Resonance Neurography (MRN)

MRN is currently considered investigational by most payers.

HD-24.7: Cone Beam Computed Tomography (CBCT)

- MD review is required
- CPT® Codes: CPT® 70486, CPT® 70487, CPT® 70488, CPT® 70480, CPT® 70482
(No separate 3-D rendering codes should be reported)

See **HD-30: Temporomandibular Joint Disease (TMJ) and Dental/Periodontal/Maxillofacial Imaging**

HD-24.8: Transcranial Doppler (CPT® 93886)

- Transcranial Doppler (TCD) is a noninvasive ultrasonic technique that measures local blood flow velocity and direction in the proximal portions of large intracranial arteries
- It is used principally in the evaluation and management of patients with cerebrovascular disease
 - ◆ Annual screening for patients with Sickle Cell Anemia (Hb-SS) and Sickle Beta Thalassemia (Sβ)
 - ◆ Evaluation of right to left cardiac shunts: Detection of microemboli in patients with stroke or TIA.

- ◆ Evaluation of intracranial occlusive disease in patients with documented stroke or TIA
- ◆ Evaluation of hemodynamic effects of known severe extra-cranial occlusive disease
- ◆ Other indications and uses of TCD generally involve in-patient settings: Evaluation of vasospasm in SAH, determination of brain death, evaluation of acute stroke and need for thrombolytics or other intervention, and intraoperative monitoring
- Screening for moyamoya disease for patient with known disease in other immediate family members.

Note: TCD studies are not indicated for evaluation of brain tumors, degenerative disease, psychiatric disorders, epilepsy, migraine or other headache disorders.

CPT® Codes	
93886	Transcranial Doppler study of the intracranial arteries; complete study
93888	Limited study (follow up)
93890	Vasoreactivity study
93892	Emboli detection without intravenous microbubble injection
93893	Emboli detection with intravenous microbubble injection

Note: CPT® 93890, CPT® 93891, CPT® 93892, CPT® 93893 represent add on services that require additional expertise, lab time, and equipment not included in the complete and limited codes.

CPT® 93890 Vasoreactivity Study: Measures response of cerebral blood flow to increased CO₂ levels (following breath holding or administration of acetazolamide); It is used to evaluate risk of stroke and significance of carotid stenosis; patients with loss of normal reactive changes are likely to be at increased risk of stroke.

CPT® 93892/CPT® 93893: Identification of right to left shunts (microembolic signals may be detected during TCD monitoring) and may indicate source of emboli in patients with stroke or TIA. TCD bubble test is very sensitive and may be superior to transthoracic and transesophageal echocardiography in detection of right to left shunts.

References

1. Latchaw RE, Kucharczyk J, Moseley ME. Imaging of the Nervous System. Philadelphia: *Elsevier*. 2005: 101-120, 1089-1100, and 1225-1239.
2. Centers for Medicare & Medicaid Services (CMS). Decision memo for magnetic resonance spectroscopy for brain tumors (CAG-00141N). January 29, 2004. Accessed October 19, 2017. <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=52&fromdb=true>.
3. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. *Neurology*. 2005 Jun 28; 64(12):2085-2089. Accessed October 19, 2017. <http://www.neurology.org/content/64/12/2085.short>

4. Cecil KM. MR spectroscopy of metabolic disorders. *Neuroimaging Clin N Am*. 2006 Feb;16(1):87-116, viii. Accessed October 19, 2017. <http://www.sciencedirect.com/science/article/pii/S1052514905001127?via%3Dihub>
5. Öz G, Tkáč I, Charnas LR, et al. Assessment of adrenoleukodystrophy lesions by high field MRSA in non-sedated pediatric patients. *Neurology*. 2005 Feb 8; 64(3):434-441. Accessed October 19, 2017. <http://www.neurology.org/content/64/3/434.abstract>
6. Moser HW and Barker PB. Magnetic resonance spectroscopy: a new guide for the therapy of adrenoleukodystrophy. *Neurology*. 2005 Feb 8; 64(3):406-407. Accessed October 19, 2017. <http://www.neurology.org/content/64/3/406.extract>
7. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. *Ann Neurol*. 2006 Nov; 60(5):508-517. Accessed October 19, 2017. <http://onlinelibrary.wiley.com/doi/10.1002/ana.20976/full>
8. Wintermark M, Meuli R, Browaeys P, et al. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. *Neurology*. 2007 Feb 27; 68(9):694-697. Accessed October 19, 2017. <http://www.neurology.org/content/68/9/694.abstract>
9. Lev MH, Segal AZ, Farkas J, et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. *Stroke*. 2001 Sep; 32(9):2021-2036. Accessed October 19, 2017. <http://stroke.ahajournals.org/content/32/9/2021>
10. Parsons MW, Pepper EM, Bateman GA, et al. Identification of the penumbra and infarct core on hyperacute noncontrast and perfusion CT. *Neurology*. 2007 Mar 6; 68:730-736. Accessed October 19, 2017. <http://www.neurology.org/content/68/10/730.abstract>
11. Haughton VM, et al. Mapping brain function with functional magnetic resonance imaging. In Latchaw RE, Kucharuczyk J, Moseley ME. *Imaging of the Nervous System*. Philadelphia: Elsevier. 2005: 89-100.
12. Håberg A, Kvistad KA, Unsgård G, et al. Preoperative blood oxygen level-dependent functional magnetic resonance imaging in patients with primary brain tumors: clinical application and outcome. *Neurosurgery*. 2004 Apr;54(4):902-915. Accessed October 19, 2017. <https://academic.oup.com/neurosurgery/article-abstract/54/4/902/2727106/Preoperative-Blood-Oxygen-Level-dependent?redirectedFrom=fulltext>
13. Medina LS, Bernal B, Dunoyer C, et al. Seizure disorders: functional MR imaging for diagnostic evaluation and surgical treatment—perspective study. *Radiology*. 2005 July; 236(1):247-253. Accessed October 19, 2017. <http://pubs.rsna.org/doi/full/10.1148/radiol.2361040690>
14. Petrella JR, Shah LM, Harris KM, et al. Preoperative functional MRI imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. *Radiology*. 2006 Sep;240(3):793-802. Accessed October 19, 2017. <http://pubs.rsna.org/doi/full/10.1148/radiol.2403051153>
15. Bendszus M and Stoll G. Technology insight: visualizing peripheral nerve injury using MRI. *Nature Clin Pract Neurol*. 2005 Nov; 1(1):45-53. Accessed October 19, 2017. <http://www.nature.com/articles/ncpneuro0017>
16. Jarvik JG, Yuen E, Haynor DR, et al. MR nerve imaging in a prospective cohort of patients with suspected carpal tunnel syndrome. *Neurology*. 2002 Jun 11; 58(11):1597-1602. Accessed October 19, 2017. <http://www.neurology.org/content/58/11/1597.short>
17. Korvenoja A, Kirveskari E, Aronen HJ, et al. Sensorimotor cortex localization: comparison of magnetoencephalography, functional MR imaging, and intraoperative cortical mapping. *Radiology*. 2006 Oct; 241(1):213-222. Accessed October 19, 2017. <http://pubs.rsna.org/doi/10.1148/radiol.2411050796>
18. De Vos W, Casselman J, Swennen GR. Cone-beam computerized tomography (CBCT) imaging of the oral and maxillofacial region: a systematic review of the literature. *Int J Oral Maxillofac Surg*. 2009 Jun;38(6):609-625. Accessed October 19, 2017. [http://www.ijoms.com/article/S0901-5027\(09\)00864-9/fulltext](http://www.ijoms.com/article/S0901-5027(09)00864-9/fulltext)
19. Alexandrov AV, Sloan MA, Tegeler CH, et al. Practice standards for transcranial doppler (TCD) ultrasound. Part II. Clinical indications and expected outcomes. *J Neuroimaging*. 2012 Jul;22(3):215-224. Accessed October 19, 2017. <http://onlinelibrary.wiley.com/doi/10.1111/j.1552-6569.2010.00523.x/abstract>

20. Pediatric Neurosurgery. *Pediatric Neurosurgery*. 2017;19
21. Tsigoulis G, Alexandrov AV. Ultrasound in Neurology. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1655-1677.

HD-25: Epistaxis

HD-25.1: Epistaxis

76

HD-25.1: Epistaxis

- All cases should go to Medical Director for review.
- Maxillofacial CT without or without and with contrast (CPT® 70486 or CPT® 70488) and/or MRI orbit, face, and/or neck without and with contrast (CPT® 70549) is appropriate based on endoscopic findings of mass lesion during ENT examination.

References

1. Kirsch CFE, Bykowski J, Aulino JM, et al. ACR Appropriateness Criteria®. Sinonasal disease. *American College of Radiology (ACR)*. Revised 2017. Accessed October 19, 2017. <https://acsearch.acr.org/docs/69502/Narrative/>.
2. Hoeffner EG, Mukherji SK, Gandhi D, et al. *Temporal bone imaging*. New York: Thieme; 2008.

HD-26: Mastoid Disease

HD-26.1: Mastoid Disease

78

HD-26.1: Mastoid Disease

- See Pediatric Head Guidelines, **PEDHD-16.2: Ear Pain**

HD-27: Hearing Loss

HD-27.1: Hearing Loss

80

HD-27.1: Hearing Loss

- MRI Head with attention to internal auditory canal without and with contrast (CPT® 70553), or MRI Head with attention to internal auditory canal without contrast (CPT® 70551) or CT Temporal bone without contrast (CPT® 70480) can be considered for hearing loss.¹ Clinical information provided should include evaluation of hearing either by bedside testing or by formal audiology.
- Limited Study MRI with attention to internal auditory canal (CPT®70540, CPT® 70542, CPT®70543) can be approved in place of MRI Head with attention to internal auditory canal when requested by the provider in the following scenarios:
 - ◆ Any sensorineural hearing loss (cochlea or auditory nerve)¹
 - ◆ Any conductive hearing loss¹(including Cholesteatoma²)
 - ◆ Cochlear implants candidate¹
 - ◆ Fluctuating hearing loss¹

Practice Note

An initial evaluation generally determines whether a patient's hearing loss is conductive (external or middle ear structures) or sensorineural (inner ear structures, such as cochlea or auditory nerve) hearing loss.^{1,2}

References

1. Angtuaco EJ, Wippold II FJ, Cornelius RS, et al. ACR Appropriateness Criteria® Hearing loss and/or vertigo. *American College of Radiology (ACR)*. Date of origin: 1996. Last review date: 2013. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69488/Narrative/>.
2. Isaacson JE and Vora NM. Differential diagnosis and treatment of hearing loss. *Am Fam Physician*. 2003 Sep 15; 68(6):1125-1132. Accessed October 19, 2017. <http://www.aafp.org/afp/2003/0915/p1125.html>

HD-28: Ear Pain (Otalgia)

HD-28.1: Ear Pain (Otalgia)

82

HD-28.1: Ear Pain (Otalgia)

- CT Temporal bone without and with contrast (CPT® 70482) or without contrast (CPT® 70480) and/or MRI Head without contrast (CPT® 70551) or without and with contrast (CPT® 70553) can be considered for:
 - ◆ Common causes of ear pain including ear infections, dental problems, sinus infection, neck problems, tonsillitis, and pharyngitis, as well as otitis media or otitis externa or no obvious cause, which do not improve with treatment over a reasonable time
 - ◆ Cerebellopontine angle or other intracranial tumor is suspected
 - ◆ Nervus intermedius neuralgia in order to exclude a structural lesion

See **HD-27: Hearing Loss**

References

1. Li JC. Otalgia. *Medscape*. Updated May 03, 2017. Accessed October 19, 2017. <http://emedicine.medscape.com/article/845173-overview>.
2. Hoeffner EG, Mukherji SK, Gandhi D, et al. *Temporal bone imaging*. New York: Thieme; 2008.

HD-29: Sinusitis

HD-29.1: Sinus Imaging in Adults

84

HD-29.1: Sinus Imaging in Adults

- There is no evidence to support advanced imaging of acute (< 4 weeks) and subacute (4 to 12 weeks) uncomplicated rhinosinusitis^{1,3}
- There is no evidence to support routine follow-up advanced imaging after treatment with clinical improvement of sinusitis¹
- CT Maxillofacial without contrast (CPT® 70486) or limited sinus CT without contrast (CPT® 76380) is considered for any of the following:
 - ◆ Acute (< 4 weeks) and sub-acute (4 to 12 weeks) rhinosinusitis in immune-deficient patients (i.e., fungal sinusitis)¹
 - ◆ Recurrent (< 30 days episodes separated by at least 10 asymptomatic days) acute/subacute/chronic rhinosinusitis.^{1,2,3}
 - ◆ Sinonasal polyposis¹
 - ◆ Chronic (> 12 weeks) sinusitis³ with at least two of the following signs and symptoms:
 - Mucopurulent drainage
 - Nasal obstruction
 - Facial pain –pressure, fullness
 - Decreased sense of smell
 - ◆ Worsening or failure to improve within 72 hours of initial management⁴
 - ◆ Acute sinusitis with no improvement in symptoms after a minimum of 4 weeks of treatment
- In addition to standard Sinus CT imaging (CPT® 70486), both CT and MRI imaging may be approved in the following scenarios:
 - ◆ Orbital and/or Intracranial complications with ocular and/or neurological deficit^{1,3,4}
 - MRI Face, Orbit, and Neck without and with contrast (CPT® 70543) **or**
 - MRI Head without and with contrast (CPT® 70553) **or**
 - MRI Head without contrast (CPT® 70551) **and/or**
 - CT Orbit without contrast (CPT® 70480) **or**
 - CT Orbit with contrast (CPT® 70481) **or**
 - CT Head without and with contrast (CPT® 70470)
 - ◆ A new obstructing sinus mass, including retention cysts and nasal polyps, that obscures the physician's view on endoscopy MRI Face, Orbit, and Neck without and with contrast (CPT® 70543) **or**
 - MRI Head without and with contrast (CPT® 70553) **or**
 - MRI Head without contrast (CPT® 70551) **and/or**
 - CT Orbit without contrast (CPT® 70480) **or**
 - CT Orbit with contrast (CPT® 70481) **or**
 - CT Head without and with contrast (CPT® 70470)
 - ◆ Fungal Sinusitis¹
 - MRI Face, Orbit, and Neck without and with contrast (CPT® 70543) **or**
 - MRI Head without and with contrast (CPT® 70553) **or**
 - MRI Head without contrast (CPT® 70551) **and/or**
 - CT Orbit without contrast (CPT® 70480) **or**
 - CT Orbit with contrast (CPT® 70481) **or**
 - CT Head without and with contrast (CPT® 70470) **or**

- ◆ One time repeat imaging may be approved in the following scenarios:
 - An ENT specialist requests the imaging **and**:
 - There is no improvement after an additional 4 weeks of conservative treatment after initial imaging was completed; **and**
 - There has been a follow-up visit since the previous imaging; **or**
 - If there is a new abnormality on exam such as obstructing mass
- ◆ CT Maxillofacial (CPT® 70486) may be approved following MRI Brain if request otherwise meets criteria for imaging of sinus disease
- ◆ 3D Rendering (CPT® 76376 or CPT® 76377) may be added if ordered by a specialist for sinus surgery preoperative planning

Practice Notes

- Rhinosinusitis is defined as inflammation of the nasal cavity and adjacent paranasal sinuses. Acute sinusitis refers to symptom duration < 4 weeks, subacute 4 to 12 weeks, and chronic > 12 weeks. Complicated sinusitis refers to symptoms suggesting spread of disease into adjacent structures, including orbital or intracranial complications.^{1,2,3}

References

1. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015 Apr; 152(2 Suppl):S1-S39. Accessed October 19, 2017. <http://journals.sagepub.com/doi/10.1177/0194599815572097>
2. Desrosiers M, Evans GA, Keith PK, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. *Allergy Asthma Clin Immunol*. 2011 Feb 10; 7(1):2. Accessed October 19, 2017. <https://aacijournal.biomedcentral.com/articles/10.1186/1710-1492-7-2>
3. Kirsch CFE, Bykowski J, Aulino JM, et al. ACR Appropriateness Criteria®. Sinonasal disease. *American College of Radiology (ACR)*. Revised 2017. Accessed October 19, 2017. <https://acsearch.acr.org/docs/69502/Narrative/>.
4. Huntzinger A. Guidelines for the Diagnosis and Management of Rhinosinusitis in Adults. *Am Fam Physician*. 2007 Dec 1; 76(11):1718-1724. Accessed October 19, 2017. <http://www.aafp.org/afp/2007/1201/p1718.html>

HD-30: Temporomandibular Joint Disease (TMJ) and Dental/Periodontal/Maxillofacial Imaging

HD-30.1: Temporomandibular Joint Disease (TMJ)	87
HD-30.2: Dental/Periodontal/Maxillofacial Imaging	87

HD-30.1: Temporomandibular Joint Disease (TMJ)

- TMJ MRI (CPT® 70336) is the diagnostic study of choice and should be reserved for those who fail a minimum of 6 weeks of non-surgical treatment and who are actively being considered for TMJ surgery
- CT Maxillofacial without contrast (CPT® 70486) or without and with contrast (CPT® 70488) may be performed when there is suspicion of bony involvement from the MRI and if primary bony pathologies are suspected clinically
- Ultrasound (CPT® 76536) can be used to look for the presence of a joint effusion and to evaluate cartilage and disk displacement with open and closed mouth imaging and to guide injections
- TMJ imaging in children with Juvenile Rheumatoid Arthritis, See **PEDHD-25: Temporomandibular Joint (TMJ) Imaging in Children**

HD-30.2: Dental/Periodontal/Maxillofacial Imaging

- All requests will be forwarded to Medical Director for review
- Cone beam CT may be supported for surgical planning when plain x-rays alone are insufficient. Potential indications include but are not limited to:
 - ◆ Impacted teeth
 - ◆ Supernumerary teeth
 - ◆ Dentoalveolar trauma
 - ◆ Root resorption
 - ◆ Foreign body
 - ◆ Odontogenic cysts, tumors, or other jaw pathology
 - ◆ Cleft pathology
 - ◆ Orthognathic surgery for dentofacial anomalies
 - ◆ Osteomyelitis and odontogenic infections (MRI is the preferred modality after x-ray, See **MS-9.1: Infection – General**)
 - ◆ Bisphosphonate-related osteonecrosis of the jaw
 - ◆ Salivary gland stones
 - ◆ Maxillofacial bone graft planning
 - ◆ Dental implants related to tooth loss from injury, trauma, or jaw pathology such as cysts, tumors, or cancer
- Some payers do not include orthodontic clinical conditions such as replacement of teeth lost due to caries or periodontal disease, non-trauma related dental implantology, or endodontic treatment not related to trauma to the natural tooth in their coverage policies
 - ◆ Thus, Cone beam CT scans in these patients would also not be included in the coverage policy
 - ◆ These coverage policies will take precedence over eviCore's guidelines
- Cone Beam CT: Report with CPT® Codes: CPT® 70486, CPT® 70487, CPT® 70488, CPT® 70480, CPT® 70482
- 3-D rendering (CPT® 76376 or CPT® 76377) should NOT be reported separately
- Cone beam CT (CBCT) may also be called i-CAT scanner or mini-CAT scanner

References

1. De Vos W, Casselman J, and Swennen GRJ. Cone-beam computerized tomography (CBCT) imaging of the oral and maxillofacial region: a systematic review of the literature. *International Journal of Oral & Maxillofacial Surgery* 2009 Jun; 38(6):609-625. Accessed October 19, 2017.
<http://www.sciencedirect.com/science/article/pii/S0901502709008649>
2. Scrivani SJ, Keith DA, and Kaban LB. Temporomandibular disorders. *N Engl J Med*. 2008 Dec 18; 359(25):2693-2705. Accessed October 19, 2017.
<http://www.nejm.org/doi/full/10.1056/NEJMra0802472>.
3. Bag AK, Gaddikeri S, Singhal A, et al. Imaging of the temporomandibular joint: an update. *World J Radiol*. 2014 Aug 28;6(8):567-582. Accessed October 19, 2017.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147437/>
4. Horner K, O'Malley L, Taylor K, et al. Guidelines for clinical use of CBCT: a review. *Dentomaxillofac Radiol*. 2015 Jan;44(1):20140225. Accessed November 28, 2017.
<http://www.birpublications.org/doi/pdf/10.1259/dmfr.20140225>.

HD-31: Tinnitus

HD-31.1: Tinnitus

90

HD-31.1: Tinnitus

- Advanced imaging is not usually indicated in the evaluation of tinnitus, unless one or more of the following signs and symptoms are present:
 - ◆ Tinnitus localized to a single ear
 - ◆ Pulsatile tinnitus
 - ◆ Focal neurological abnormalities
 - ◆ Asymmetric hearing loss
- If one or more of these signs and symptoms are present, the following advanced imaging studies can be considered:
 - ◆ MRI Head without and with contrast^{1,2,3} (CPT® 70553) **or**
 - ◆ CT Temporal bone³ without or without and with contrast (CPT® 70480 or CPT® 70482) **or**
 - ◆ MRI Head with attention to internal auditory canal³ without and with contrast (CPT® 70553) or MRI Head and internal auditory canal³ without contrast (CPT® 70551) **or**
 - ◆ Limited Study MRI with attention to internal auditory canal (CPT® 70540, CPT® 70541, CPT® 70542, CPT® 70543) can be approved in place of MRI Head with attention to internal auditory canal when requested by the provider
 - ◆ MRA Head without contrast (CPT® 70544) and/or MRA Neck without contrast (CPT® 70547) or MRA Neck with contrast (CPT® 70548) or CTA Head (CPT® 70496) and/or CTA Neck (CPT® 70498) can be added if there is suspicion of vascular lesions
 - ◆ Head CT^{1,2} without contrast (CPT® 70450) or Head CT without and with contrast (CPT® 70470) can be approved for:
 - Suspected intracranial extension of a tumor
 - Patient is unable to have an MRI

Practice Notes

The history in patients with tinnitus should include a description of the tinnitus (episodic or constant, pulsatile or non-pulsatile, rhythmicity, pitch, quality of the sound), as well as inciting or alleviating factors. Continuous and pulsatile tinnitus are more concerning for an underlying and significant disorder.² Audiometric assessment can be used as initial diagnostic testing^{1,2,3} particularly in patients with tinnitus that is unilateral, persistent (> 6 months) or associated with hearing difficulties.

References

1. Vattoth S, Shah R, and Curé JK. A compartment-based approach for the imaging evaluation of tinnitus. *AJNR Am J Neuroradiol*. 2010 Feb;31(2):211-218. Accessed October 19, 2017. <http://www.ajnr.org/content/31/2/211>
2. Crummer RW and Hassan GA. Diagnostic approach to tinnitus. *Am Fam Physician*. 2004 Jan 1;69(1):120-126. Accessed October 19, 2017. Accessed October 19, 2017. <http://www.aafp.org/afp/2004/0101/p120.html>
3. Angtuaco EJ, Wippold II FJ, Cornelius RS, et al. ACR Appropriateness Criteria® Hearing loss and/or vertigo. *American College of Radiology (ACR)*. Date of origin: 1996. Last review date: 2013. Accessed October 18, 2017. <https://acsearch.acr.org/docs/69488/Narrative/>.
4. American Speech-Language-Hearing Association, Tinnitus Triage Guidelines. 2010 Oct. Accessed October 19, 2017. <https://www.asha.org/Articles/Tinnitus-Triage-Guidelines/>
5. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. *Otolaryngol Head and Neck Surg*. 2014 Oct;151(2 Suppl):S1-S40. Accessed October 19, 2017. <http://journals.sagepub.com/doi/10.1177/0194599814545325>

HD-32: Eye Disorders

HD-32.1: Eye Disorders

93

HD-32.1: Eye Disorders

- MRI Head without and with contrast (CPT® 70553) and/or MRI Orbit without and with contrast (CPT® 70543) or MRI Head without contrast (CPT® 70551) and/or MRI Orbit without contrast (CPT® 70540). May be considered in the following scenarios*:
 - ◆ Anisocoria which is of new onset (e.g. not present in previous photographs) and \geq 1 mm
 - ◆ Acute or progressive vision loss due to any cause, including suspected optic neuritis
 - ◆ Ophthalmoplegia
 - ◆ Binocular Diplopia
 - ◆ Horner's Syndrome, for which CT Neck with contrast and/or CT Chest with contrast may be considered in addition to the head or orbital imaging
 - ◆ CT Head without contrast may be substituted for the MRI imaging if there has been a head injury
- Evaluation of a third nerve palsy may be accomplished with an MRI Head without and with contrast (CPT® 70553) and/or MRA Brain without contrast (CPT® 70544)
 - ◆ CT Head without and with contrast (CPT® 70470) and/or CT Orbit with contrast (CPT® 70481) can be approved if there is a clinical question of blood in the subarachnoid space
- If MRI is contraindicated or cannot be performed, CT Head without and with contrast (CPT® 70470), CT Orbit with contrast (CPT® 70481) or CT Orbit without and with contrast (CPT® 70482) may be considered as substitutes

See **HD-16: Multiple Sclerosis (MS) and Related Conditions**

Practice Notes

*Advanced imaging of the brain and orbit are not routinely paired. Medical necessity for each region is needed to image both regions, based on suspicion of these disorders.

Orbital imaging alone may be sufficient unless other signs or symptoms suggest brain involvement. Signs or symptoms strongly suggestive and localizing to orbital disease include proptosis, conjunctival injection, chemosis, eye pain, enophthalmos, gaze-evoked amaurosis, eyelid retraction, unilateral optic disc swelling, choroidal and retinal folds, optociliary shunt vessels, and numb cheek syndrome.

Non-localizing symptoms and signs, for which both brain and orbit imaging may be indicated, include bilateral optic disc swelling, papilledema, diplopia, headache, relative afferent pupillary defect, visual field defects.

References

1. Wippold II FJ, Cornelius RS, Berger KL, et al. ACR Appropriateness Criteria® Orbits, vision and visual loss. *American College of Radiology (ACR)*. Date of origin: 1999. Last review date: 2012. Accessed October 19, 2017. <https://acsearch.acr.org/docs/69486/Narrative/>
2. Quisling SV, Shah VA, Lee HK, et al. Magnetic resonance imaging of third cranial nerve palsy and trigeminal sensory loss caused by herpes zoster. *J Neuroophthalmol*. 2006 Mar; 26(1):47-48. Accessed October 19, 2017. <http://journals.lww.com/jneuro-ophthalmology/pages/articleviewer.aspx?year=2006&issue=03000&article=00010&type=abstract>
3. Physiologic anisocoria. *Am Acad Ophthalmol*. Accessed October 19, 2017. <https://www.aao.org/BcscSnippetDetail.aspx?id=4c18b321-00ec-427b-af76-0b2b5548b920>
4. Lee JH, Lee HK, Lee DH, et. al., Neuroimaging strategies for three types of horner syndrome with emphasis on anatomic location. *AJR Am J Roentgenol*. 2007 Jan; 188(1):W74-W81. Accessed October 19, 2017. <http://www.ajronline.org/doi/full/10.2214/AJR.05.1588>
5. Szatmáry G. Imaging in patients with visual symptoms. *Continuum*. 2016 Oct;22(5):1499-1528. Accessed October 19, 2017. http://journals.lww.com/continuum/Abstract/2016/10000/Imaging_in_Patients_With_Visual_Symptoms.11.aspx.

HD-33: Acoustic Neuroma and Other Cerebellopontine Angle Tumors

HD-33.1: Acoustic Neuroma & Other Cerebellopontine Angle Tumors

96

HD-33.1: Acoustic Neuroma and Other Cerebellopontine Angle Tumors

- Clinical information should include evaluation of hearing either by bedside testing or by formal audiology
- Initial diagnosis can be accomplished with MRI Head without and with contrast (CPT® 70553) which should be done with attention to the internal auditory canals. Clinical information provided should include evaluation of hearing either by bedside testing or by formal audiology
- MRI Head without contrast (CPT® 70551) may be approved if performed with FIESTA protocol
- MRI Orbits, Neck, or Face without and with contrast (CPT® 70543) may be considered with audiologic or clinical features of retrocochlear hearing loss and a negative head MRI and in the rare patient in whom a detailed search is indicated for both a lesion of the cerebellopontine angle **and** lesions of the cerebral hemispheres
- After surgical resection, MRI Head without and with contrast with attention to the internal auditory canals (CPT® 70553) is performed at 6 to 12 months to document the completeness of tumor removal and to serve as a baseline for further follow-up. Assuming complete tumor removal, additional follow up is done at 5 and 10 years. If the findings at 10 years are normal, no further imaging should be performed unless new clinical symptoms occur
- Following stereotactic radiation therapy or continued observation without treatment: MRI Head without and with contrast with attention to the internal auditory canals (CPT® 70553) is performed at 6 months and then annually

References

1. Hingwala, D, Chatterjee S, Kesavadas C, et al. Applications of 3D CISS sequence for problem solving in neuroimaging. *Indian J Radiol Imaging*. 2011 Apr-Jun;21(2): 90–97. Accessed October 19, 2017. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137865/>
2. Yousry I, Camelio S, Schmid UD, et al. Visualization of cranial nerves I-XII: value of 3D CISS and T2-weighted FSE sequences. *Eur Radiol*. 2000; 10(7):1061-1067. Accessed October 19, 2017. <https://link.springer.com/article/10.1007/s003300000452>
3. Kutz JW, Roland PS, and Isaacson B. Acoustic neuroma treatment & management. *Medscape*. Updated Jan. 25, 2017. Accessed October 19, 2017. <https://emedicine.medscape.com/article/882876-treatment>

HD-34: Pineal Cysts

See Pediatric Head Guidelines, [PEDHD-13.2: Pineal Cysts](#)

HD-35: Arachnoid Cysts

See Pediatric Head Guidelines, [PEDHD-13.1: Arachnoid Cysts](#)

HD-36: Nuclear Medicine

- Nuclear Medicine
 - ◆ Nuclear medicine studies may be used in the evaluation of some head/brain disorders, and other rare indications as well:
 - Brain Scintigraphy with or without vascular flow (any one of CPT® 78600, CPT® 78601, CPT® 78605, or CPT® 78606)
 - Establish brain death (rarely done in outpatient setting)
 - Brain Imaging SPECT with Technetium-99m or thallium-201 (CPT® 78607)¹
 - Immunocompromised patients with mass lesion detected on CT or MRI for differentiation between lymphoma and infection
 - In distinguishing recurrent brain tumor from radiation necrosis
 - Brain Imaging Vascular Flow (CPT® 78610)
 - Cerebral ischemia
 - Establish brain death
 - CSF Leakage Detection (CPT® 78650)
 - Evaluation of CSF rhinorrhea, otorrhea, or refractory post-lumbar puncture headache
- Suspected normal pressure hydrocephalus with gait disturbance and either dementia or urinary incontinence
- Radiopharmaceutical Dacryocystography (CPT® 78660)
 - Suspected obstruction of nasolacrimal duct due to excessive tearing
- Cisternogram (CPT® 78630) can be approved for the following:
 - ◆ Known hydrocephalus with worsening symptoms
 - ◆ Suspected obstructive hydrocephalus
- Cerebrospinal Ventriculography (CPT® 78635) can be approved for the following:
 - ◆ Evaluation of internal shunt, porencephalic cyst, or posterior fossa cyst
- Nuclear Medicine Shunt Evaluation (CPT® 78645) and CSF Flow SPECT (CPT® 78647) can be approved for the following:
 - ◆ Suspected malfunction of ventriculoperitoneal, ventriculopleural, or ventriculovenous shunts.
- Imaging SPECT with Ioflupane I-23 (CPT® 78607) can be approved for differentiation of Parkinsonian syndrome (PS) and non-neurodegenerative disorders, such as essential tremor (ET) or drug-induced tremor, due to the overlap of clinical symptoms.² DAT-SPECT has significant impact on clinical diagnosis and management of diagnostic uncertainty in cases of PS.³ See **HD-15: Movement Disorders**

Reference

1. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is there a role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? *Neurodegener Dis*. 2015 Apr;15(2):81-86. Accessed November 1, 2017. <https://www.karger.com/Article/FullText/370116>.

HD-37: Sleep-Related Requests

HD 37.1: General Guidelines Sleep-Related Requests

101

HD 37.1: General Guidelines Sleep-Related Requests

- Oral Appliance: There is a lack of published case-controlled clinical studies in Sleep literature validating the use of advanced imaging with respect to oral appliance therapy (pretreatment assessment). Previous literature has demonstrated support for cephalometric studies (x-ray)¹ in predicting treatment success. Nasoendoscopy (sedated and non-sedated with provocative maneuvers such as Mueller maneuver) has been helpful as well in this regard.² Routine use of advanced is not supported at this time
- Hypersomnolence: MRI Brain with and without contrast (CPT® 70553) may be indicated when there are focal neurologic signs or suspicion for an inflammatory neurologic process as the etiology. Recognition and treatment of a comorbid sleep disorders is paramount, and a complete neurologic history and examination should precede any request for advanced imaging³
- Central Sleep Apnea: MRI Brain with and without contrast (CPT® 70553) may be indicated for unexplained central sleep apnea syndrome when a primary CNS etiology is suspected; i.e., unassociated with CHF, COPD or other potential etiology. Specific etiologies should be stated for imaging requests, including but not limited to, suspected Chiari malformation, stroke, CNS demyelinating disease, posterior fossa lesion, anoxia or infection⁴

References

1. Guarda-Nardini L, Manfredini D, Mion M, et al. Anatomically based outcome predictors of treatment for obstructive sleep apnea with intraoral splint devices: a systematic review of cephalometric studies. *J Clin Sleep Med*. 2015;11(11):1327-1334. Accessed October 11, 2017. <http://jcs.m.aasm.org/ViewAbstract.aspx?pid=30314>.
2. Sutherland, K, Vanderveken OM, Tsuda H, et al. Oral appliance treatment for obstructive sleep apnea: an update. *J Clin Sleep Med*. 2014;10(2):215-227. Accessed October 11, 2017. <http://jcs.m.aasm.org/ViewAbstract.aspx?pid=29343>.
3. Chervin RD. Use of clinical tools and tests in sleep medicine. In: *Principles and Practice of Sleep Medicine*. Kryger MH, Roth T, Dement WC. (eds). Elsevier Saunders: St Louis 2011. p.666.
4. Deak MC and Kirsch DB. Sleep-disordered breathing in neurologic conditions; *Clin Chest Med*. 2014 Sep;35(3):547–556. Accessed October 11, 2017. <https://www.ncbi.nlm.nih.gov/pubmed/25156770>.